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REGULATION OF APOPTOSIS BY THE MUSCLE REGULATORY
TRANSCRIPTION FACTOR MYOD
TERRI J. HARFORD
ABSTRACT
We have previously reported that the level of MyoD expression correlates with
the level of apoptosis that occurs in a subpopulation of skeletal myoblasts
induced to differentiate by serum withdrawal. Herein we document that MyoD
expression dictates the apoptotic threshold in myoblasts and fibroblasts in
response to a variety of apoptotic stimuli. Specifically, re-expression of MyoD in
skeletal myoblasts rendered defective for both differentiation and apoptosis by
the expression of oncogenic Ras restores their ability to undergo both
differentiation and apoptosis in response to serum withdrawal. Further, using a
fibroblast cell line expressing an estrogen receptor:MyoD fusion protein, we have
determined that addition of estrogen sensitizes these fibroblasts to apoptosis
induced by serum withdrawal, or by treatment with etoposide or thapsigargin.
RNAi mediated silencing of MyoD in either 23A2 or C2C12 myoblasts renders
these cells resistant to apoptosis induced by serum withdrawal, or by treatment
with etoposide or thapsigargin.

Finally, MyoD mediated regulation of the

apoptotic response to these various stimuli correlates with the level of induction
of the pro-apoptotic Bcl-2 family member PUMA.

vii

TABLE OF CONTENTS

ABSTRACT..................................................................................................

Page
vii

LIST OF TABLES.........................................................................................

x

LIST OF FIGURES.....................................................................................

xi

CHAPTER
I. INTRODUCTION
1.1

Skeletal Myogenesis....................................................

1

1.2

Myogenic transcription factors.....................................

4

1.3

Skeletal myoblast model system..................................

7

1.4

General Apoptosis........................................................

9

1.5

Extrinsic apoptotic pathway..........................................

10

1.6

Intrinsic apoptotic pathway...........................................

12

1.7

Overview of mitochondrial disruption in other systems

16

1.8

Caspases......................................................................

17

1.9

Serine proteases in apoptosis......................................

19

1.10

Molecular mechanisms of apoptosis in sk. Myoblasts

20

1.11

Transcription factors associated with apoptosis..........

21

1.11.1 p53....................................................................

22

1.11.2 FOXO3a............................................................

23

viii

II. MATERIALS AND METHODS
2.1

Cells and cell culture...................................................

25

2.2

Transient transfection.................................................

26

2.3

Immunoblot analysis..................................................

26

2.4

ELISA.........................................................................

28

2.5

Stable transduction of shRNA for gene knockdown...

29

2.5.1 Assembly of lentiviral vector for
transduction of myoblasts.................................

29

2.5.2 Stable transduction of myoblasts with lentivirus
containing pKLO.1 puro-MyoD shRNA or pKLO.1
puro (control vector).........................................

30

2.6

Semi-quantitative RT-PCR.........................................

30

2.7

RT-PCR......................................................................

31

III. RESULTS
3.1

MyoD regulates the apoptosis associated with
differentiation..............................................................

3.2

MyoD regulates apoptosis in response to
other apoptotic stimuli.................................................

3.3

33
50

MyoD mediated regulation of the apoptotic
response correlates with the level of induction
of the pro-apoptotic Bcl-2 family member PUMA......

55

IV. DISCUSSION
4.1

Overview.....................................................................

73

4.2

Future directions.........................................................

86

4.3 Conclusions.....................................................................

91

REFERENCES.......................................................................... ......

92

ix

LIST OF TABLES
Page
Table 1.

Primers for PCR......................................................................

x

32

LIST OF FIGURES
Figure

Page

1. Skeletal myogenesis..................................................................................

3

2. MyoD and E-proteins bind to canonical E box..........................................

5

3. Extrinsic Apoptotic Pathway.....................................................................

11

4. Bcl-2 family of proteins.............................................................................

13

5. Intrinsic Apoptotic Pathway......................................................................

15

6. Caspase structure and activation.............................................................

18

7. MyoD expression is reduced in oncogenic Ras
expressing skeletal myoblasts.....................................................................

35

8. Oncogenic Ras-expressing myoblasts have reduced
apoptotic potential.......................................................................................

36

9. Transient ectopic expression of MyoD in G12V H-Ras
myoblasts is sufficient to restore differentiation..........................................

38

10. Ectopic expression of MyoD in G12V H-Ras expressing
myoblasts restores apoptotic potential in response to serum withdrawal...

40

11. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein sensitizes to the induction of differentiation
or the associated apoptosis in response to serum withdrawal..................

42

12. MyoD protein expression correlates with MHC expression between
cell lines utilized........................................................................................

43

13. Lentiviral transduction of shRNA against MyoD reduces the
expression of MyoD in 23A2 myoblasts.....................................................

xi

45

14. Lentiviral transduction of shRNA against MyoD reduces
the expression of MyoD in C2C12 myoblasts..............................................

46

15. Stable silencing of MyoD expression in 23A2 and C2C12
skeletal myoblasts represses differentiation.................................................

48

16. Stable silencing of MyoD expression in skeletal
myoblasts represses apoptosis as a consequence of serum withdrawal....

49

17. MyoD expression enhances apoptosis induced by agents which
cause DNA damage....................................................................................

51

18. MyoD expression enhances apoptosis induced by agents which
cause ER-stress..........................................................................................

52

19. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads enhanced apoptosis induced
by agents which cause DNA damage or ER-Stress..................................

54

20. Elevated PUMA mRNA expression levels as a consequence
of serum withdraw correlates with MyoD expression levels in myoblasts...

56

21. Elevated PUMA protein expression levels as a consequence
of serum withdraw correlates with MyoD expression levels in myoblasts....

57

22. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads to PUMA induction in response
to serum withdrawal......................................................................................

59

23. Reduced MyoD expression in 23A2 myoblasts abrogates
increased PUMA expression in response to etoposide................................

xii

61

24. Reduced MyoD expression in 23A2 myoblasts abrogates
increased PUMA expression in response to thapsigargin............................

62

25. Reduced MyoD expression in C2C12 myoblasts abrogates
increased PUMA expression in response to etoposide...............................

63

26. Reduced MyoD expression in C2C12 myoblasts abrogates
increased PUMA expression in response to thapsigargin...........................

64

27. MyoD activation in 10T1/2 fibroblasts expressing an
estrogen receptor MyoD fusion protein leads to PUMA
induction in response to etoposide............................................................. .

66

28. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads to PUMA induction in
response to thapsigargin.............................................................................

67

29. Basal expression levels of p53 in myoblasts transduced with
shRNA against MyoD is not affected.........................................................

69

30. PUMA mRNA induction does not require de novo translation
in myoblasts................................................................................................

71

31. PUMA mRNA induction does not require de novo translation in
10T1/2 fibroblasts expressing estrogen receptor MyoD fusion protein.......

72

32. A Role for MyoD in the regulation of PUMA and apoptosis....................

75

33. Apoptotic factors discovered in C. elegans and mammalian homologs.

79

xiii

LIST OF ABBREVIATIONS
ABTS

2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)

AEBSF

4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride

AIF

Apoptosis inducing factor

Apaf-1

Apoptotic Protease Activating Factor 1

ARF

Alternative Reading Frame

ASSP

Apoptotic stimulating protein of p53

ATF-1

Activating Transcription Factor-1

ATP

Adenosine Triphosphate

A/T

Adenosine/

AU

Adenosine uridine

Bad

Bcl-2 antagonist of cell death

Bak

Bcl-2 associated killer

Bax

Bcl-2 associated X protein

Bcl-2

B-cell Lymphoma 2

Bcl-xL

B-cell lymphoma extra large

Bcl-w

B cell lymphoma -W

BH-3 only

Bcl-2 Homology domain 3 only

bHLH

Basic helix loop helix

Bid

Bcl-2 homology interacting domain death agonist

Bim

BCL-2-interacting mediator of cell death

BME

Beta mercaptoethanol/Basal Medium Eagle

BSA

Bovine Serum Albumin

xiv

C

Control

Caspase

Cysteine aspartic acid

cdc25

Cyclin dependent kinase 25

CDK4

Cyclin dependent kinase 4

cDNA

copy deoxyribonucleic acid

CEBP!

CCAAT enhancer binding protein alpha

ced-3

Cell death defective-3

ced-4

Cell death defective-4

ced-9

Cell death defective-9

CHAPS

3-[3-(chloramidopropyl)dimethylammonio]-1-propanesulfonic acid

CHiP

Chromatin immunoprecipitation

CHX

Cyclohexamide

Ct

Coefficient time

DNA

Deoxyribonucleic acid

Diablo

Direct inhibitor of apoptosis binding protein with low pi

DM

Differentiation medium

DMEM

Dulbecco modified eagle medium

dNTPs

Deoxyribonucleotriphosphates

DR5

Death receptor 5

DTT

Dithiothreitol

EDTA

Ethylenediaminetetraacetic acid

egl-1

Egg-laying defective-1

ELISA

Enzyme linked immunosorbant assay

xv

EMSA

Electromobility shift assay

ER

Estrogen receptor

ESCs

Embryonic stem cells

FADD

Fas-associated death domain protein

FasL

Fas ligand

FBS

Fetal bovine serum

FLIP

FLICE-inhibitory protein

FLISP

Fluorescently labeled inhibitor of serine protease

FOXO3a

Forkhead box-3a

GADD45

Growth arrest and DNA-damage-inducible 45

GAPDH

Glyceraldehyde phosphodehydrogenase

GFP

Green fluorescent protein

GM

Growth medium

HATs

Histone acetyl transferases

HDACS

Histone deacetyltransferases

HLH

Helix loop helix

HLH-2

Helix loop helix -2

HLH-3

Helix loop helix-3

HRP

Horse radish peroxidase

Hsp70

Heat shock protein 70

IAPs

Inhibitor of apoptosis

Id

Inhibitor of differentiation protein

IGFs

Insulin-like growth factors

xvi

Mcl1

Myeloid cell leukemia sequence 1

MEF2

Myocyte enhancer factor-2

mexp

Experimental median

MHC

Myosin heavy chain

MNase

Micrococcal nuclease

MOMP

Mitochondrial outer membrane potential

MOPS

3-(N-Morpholino)propanesulfonic acid; n-(3-sulfopropyl orpholine);

MRFs

Muscle regulatory factors

MRF4

Muscle Regulatory factor-4

mRNA

Messenger Ribonucleic acid

Myf5

Myogenic factor-5

MyoD

Myogenic differentiation

OD405

Optical density at 405 nm wavelength

P

Parental

PMSF

Phenyl methylsufonylfluoride

PNPP

p-Nitrophenyl Phosphate, Disodium Salt

PPAR!

Peroxisome proliferators-activated receptor alpha

PPAR!

Peroxisome proliferators-activated receptor gamma

P/S

Penicillin/streptomycin

P-ser

Phosphatidyl serine

P-thr

Phosphatidyl threonine

P-tyr

Phosphatidyl tyrosine

PUMA

p53 upregulated modulator of apoptosis

xvii

Puro

Puromycin

PVDF

Polyvinylidene difluoride

qPCR

Quantitative polymerase chain reaction

Ras

Rat sarcoma

Rb

Retinoblastoma

RNAi

Ribonucleic acid interference

RT-PCR

Reverse-transcription-polymerase chain reaction

SDS

Sodium dodecyl sulfate

SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
shRNA

Short hairpin ribonucleic acid

Smac

Second mitochondria derived activator of caspases

SMAD3

Mothers against decapentaplegic homolog 3

STAT1

Signal transducer and activator of transcription-1

tBid

Truncated Bid

TGF"

Transforming growth factor beta

TNF

Tumor necrosis factor

TRAIL

TNF related apoptosis inducing ligand

TBS-T

Tris buffered saline with Tween 20

UCP3

Uncoupling protein 3

XIAP

x linked inhibitor of apoptosis

z-VDVAD-fmk Benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluorom
ethylketone

xviii

CHAPTER I
INTRODUCTION
While all can agree the study of apoptosis is critical to the understanding
of cancer and to elucidate potential therapeutic targets for cures, we must not
overlook the importance of understanding the tightly regulated apoptosis as it
applies to the healthy development of multicellular organisms as well as in
maintaining homeostasis. In understanding the regulation of apoptosis in this
context, we can utilize the knowledge gained to improve on stem cell based
therapies currently used in the treatment of degenerative diseases such as
muscular dystrophies and for the purpose of cardiac repair (Dona, et al. 2003,
Menasche 2004, Sandri et al. 2001, Scorsin et al. 2000, Skuk and Tremblay
2003, Suzuki et al. 2001, Taylor et al. 1998). Once we are able to determine the
molecular mechanisms which determine the fate of cells during differentiation
and the associated apoptosis, we will have potential novel targets that can be
manipulated to improve the efficacy of these stem cell based therapies.

1

1.1 Skeletal Myogenesis

The formation of skeletal muscle during development or in response to
muscle damage is achieved through the process of myogenesis. Myogenesis
can be divided into two separate temporal events. Determination is the process
through which multipotential stem cells are committed to the myogenic lineage.
Differentiation is the process through which myoblasts become myotubes (Figure
1). Controlling myogenesis is a family of muscle regulatory transcription factors
(MRFs). Although expression of any of these factors will induce the conversion
of multipotent stem cells to myoblasts (Tapscott 2005), determination, in vivo is
defined by the expression of two MRFs, MyoD and Myf5. Myogenin and MRF4
are required for differentiation (Perry and Rudnicki 2000). Differentiation of
skeletal myoblasts is a complex process composed of temporally separate
events (de la Serna 2001). Actively dividing myoblasts must first exit the cell
cycle at a specific point, during G1, express muscle specific genes such as
myosin heavy chain (MHC) and fuse to form multinucleated myotubes (Rudnicki
and Jaenisch 1995). Differentiation is positively regulated by the activation of the
myogenic regulatory factors MyoD, myogenin, Myf5 and MRF4. These basic
helix-loop-helix transcription factors activate the gene expressing of the cell cycle
inhibitor p21Waf-1, which leads the cell to exit the cell cycle, followed by genes
expressing skeletal muscle protein such as myosin heavy chain (MHC) (Zhang et
al. 1999).
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DETERMINATION

DIFFERENTIATION

differentiation

MyoD, Myf5
expression

Differentiated
myotube

Culture in DM
Or at high density
Multipotent
stem cells

apoptosis

Myoblast

Apoptotic cells

Figure 1. Skeletal myogenesis. Multipotential stem cells upon expression of
MyoD or Myf5 are committed to the myogenic lineage. Upon activation of these
myogenic transcription factors, actively dividing myoblasts exit the cell cycle and
begin to express muscle specific proteins and later fuse to form multinucleated
myotubes. A subpopulation of these myoblasts will undergo apoptosis rather than
differentiation.
3

1.2 Myogenic transcription factors

Each of the four MRFs shares two characteristic regions: a helix-loop helix (HLH)
region and a basic region. The helix-loop-helix region is required for dimerization
and the basic region is required for DNA binding (Davis et al. 1990 and Voronova
et al. 1990). There are two classes of bHLH proteins: Class I bHLH proteins, also
referred to as E proteins, which include E12, E47, HEB!, and HEB" and
Daughterless and these are expressed in many different tissues. Class II bHLH
proteins include MyoD, myogenin, and achaete-scute and are expressed in a
tissue specific manner. Class I bHLH proteins can form homo- or hetero-dimers,
however the Class II bHLH proteins typically form hetero-dimers with Class I
bHLH proteins instead of homo-dimers (Murre et al. 1989). Class I: Class II
hetero-dimers can bind both canonical and non-canonical E Boxes MyoD and E
proteins contain a conserved structure of a basic region required for binding DNA
at specific E boxes and a HLH region required for hetero-dimerization to E
proteins. Once the MyoD:E-protein heterodimer binds E boxes found in myogenic
promoters and chromatin remodeling occurs, transcription of genes required for
differentiation begins. MEF2 proteins are also found to bind A/T rich regions in
myogenic promoters and act in a co-operative manner with MyoD to drive
transcription of the myogenic program. (Blackwell and Weintraub 1990) (Figure
2).
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CANNTG

CANNTG
E-Box

A/T rich region

E-Box

Muscle gene
Myogenin
MHC
p21

MyoD
E12/47
MEF2

Figure 2. MyoD and E-proteins bind to canonical E box. MyoD and E proteins
contain a conserved structure of a basic region required for binding DNA at
specific E boxes and a HLH region required for hetero-dimerization to E proteins.
Once the MyoD:E-protein heterodimer binds E boxes found in myogenic
promoters and chromatin remodeling occurs, transcription of genes required for
differentiation begins. MEF2 proteins are also found to bind A/T rich regions in
myogenic promoters and act in a co-operative manner with MyoD to drive
transcription of the myogenic program.
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The MyoD protein shares sequence identity among mammalian species
(88-93%) and zebra fish (73%). Additional homologues can be found in C.
elegans (HLH1), Drosophila (Nautilus) and in jelly fish (Ci-MyoD). In muscle
specific promoters, MyoD/E-protein hetero-dimers typically bind two canonical E
boxes and work cooperatively with myocyte enhancing factor (MEF) proteins
bound to A/T rich regions in promoters also found near the E boxes (Gossett et
al. 1989 and Bergstrom et al. 2002). Interestingly, MyoD is found bound to the
myogenin promoter in myoblasts cultured in growth media (GM), but is
transcriptionally silent. MyoD transcription repression is achieved by the
methyltransferase Suv39H1. Suv39H1 methylates the chromatin at the myogenin
promoter (Harter and Mal 2003 and Mal 2006). Additionally, histone deacetylases (HDACs) are also present at the promoters, blocking transcription
activation by preventing acetylation of histones (Dillworth et al. 2004). Upon
serum withdrawal, histone acetyltransferases (HATs) are recruited to myogenic
promoters, chromatin is remodeled and transcription will commence (Sartorelli et
al. 2005). Recruitment of chromatin remodeling complexes is required to activate
the transcription of the myogenic program. An additional level of regulation of
expression of the myogenic program occurs through the Id proteins. Id proteins
function to block differentiation by binding E proteins or the MRFs (Friday et al.
2003, and Megeney et al. 1995). Binding of Id to E proteins or MRFs sequesters
these factors in the cytosol. Once serum is withdrawn, Id is rapidly degraded, and
the E protein or MRF is free to translocate to the nucleus to transcribe the
myogenic suite of genes.
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1.3 Skeletal myoblast model system

Since the muscle regulatory transcription factor (MRF) family consisting of
Myf-5, MyoD, myogenin and MRF4, was discovered, skeletal myogenesis has
served as the model for understanding signaling events regulating cell lineage
determination and differentiation. Detailed information about the mechanistic
regulation of myogenesis has come from studies using established mouse
myoblast cell lines. The most commonly used myoblast cell lines are either
isolated from C3H mice (C2C12 and BC3H-1) or derived from multipotent nonspecified 10T1/2 fibroblasts also isolated from C3H mice (23A2 myoblasts).
These fibroblasts were treated with 5 azacytidine, which blocks re-methylation of
DNA, then selected for the expression of MyoD and the ability to undergo
differentiation as determined by the expression of MHC or myogenin (Pinney et
al. 1988). Additionally, 10T1/2 fibroblasts expressing a MyoD: estrogen receptor
fusion protein is also utilized, where a MyoD estrogen receptor fusion protein is
expressed but kept inactive until addition of estradiol to the culture medium
(Pinney et al. 1988). In vivo, circulating mitogens keep myoblasts in an actively
dividing and undifferentiated state. Differentiation of myoblasts occurs in
response to a decrease in mitogens after appropriate migration during
development. To imitate this response in vitro, skeletal myoblasts are switched
from culture in GM (medium plus 10-20% fetal bovine serum) to culture in
differentiation medium (DM) (medium with low (2%) or no serum) (Olson 1992).

7

23A2 skeletal myoblasts are 10T1/2 fibroblasts committed to the myogenic
pathway through the expression of MyoD (Pinney et al. 1988). The 23A2
myoblasts can be induced in vitro to differentiate by switching cultured cells from
GM to DM (Dee et al. 2002). Myoblasts can also be induced to differentiate by
allowing cultures to grow to confluence in GM or when cells are grown without a
fresh supply of serum (Dee et al. 2002).

Growth factors contribute to the

regulation of cell differentiation by activating specific transmembrane receptors,
leading to the stimulation of multiple intracellular signal transduction pathways.
MRFs are kept inactive in undifferentiated actively dividing myoblasts by
signaling pathways initiated by growth factors or mitogens, such as fibroblast
growth factor-2 (FGF-2) or transforming growth factor-" (TGF") (Ludolph and
Konieczny 1995, Campbell et al. 1998). Low concentrations of insulin-like growth
factors (IGFs) enhance myoblast differentiation whereas high concentrations
inhibit their differentiation (Florini and Ewton 1996, Weyman and Wolfman 1998)
by acting to promote cell proliferation.

We (Dee et al. 2002) and others (Wang and Walsh 1996) have previously
reported that when induced to differentiate in response to mitogen withdrawal,
approximately 30% of myoblasts will undergo apoptosis instead of differentiation.
While the apoptotic process in other cell systems has been comprehensively
investigated, the apoptotic process as a consequence of differentiation in skeletal
myoblasts is only now emerging.
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1.4 General Apoptosis

Apoptosis is a tightly regulated form of cell death that has the ability to
clear unwanted cells without the induction of an immune response. Apoptosis is
characterized by chromatin condensation, nuclear fragmentation, membrane
blebbing and finally clearance of the apoptotic body via macrophages (Kerr et al.
1972). Apoptosis is important developmentally and in tissue homeostasis. Most
of our current understanding of the mechanisms in apoptosis came from studies
done in C. elegans. (Horvitz 1999). During maturation of the nematode, 1090
cells are formed but 131 of these cells undergo apoptosis at specific times. In
exploring the mechanisms responsible for the well orchestrated apoptotic
program in C. elegans, many genes were uncovered to play an integral part in
the cell death program (Ellis and Horvitz 1991). Apoptosis can be triggered by a
variety of stimuli, such as genetic damage, cellular stresses, cellular responses
to external cues, or by aging. There are two predominant pathways cells utilize to
carryout apoptosis; the intrinsic pathway and the extrinsic pathway, which will be
discussed next. It is important to note that there is cross talk between these two
pathways, both upstream and downstream of the mitochondria.

9

1.5 Extrinsic apoptotic pathway

The extrinsic apoptotic pathway is triggered by external signals which are
transduced to the cell via transmembrane receptors called death receptors.
These death receptors are part of the TNF receptor gene family (Locksley et al.
2001). In skeletal myoblasts, the death receptor 5 (DR5) plays an important role
in apoptosis (O’Flaherty et al. 2005). Upon binding the TNF related apoptosisinducing ligand (TRAIL), the DR5 receptor trimerizes signaling the recruitment of
cytosolic adapter molecules to bind the cytosolic portion of the receptor
(Sartorius 2001). Binding of the adapter molecule Fas associated death domain
protein (FADD) to DR5 leads to the association of FADD with pro-caspase 8.
Pro-caspase 8 then can auto-activate itself through a proteolytic cleavage
(Denault 2002). Once activated, caspase 8 perpetuates the apoptotic cascade by
either cleaving caspase 3 or cleaving the proapoptotic Bcl-2 protein Bid which,
when activated, translocates to the mitochondria to activate Bax or Bak to initiate
mitochondrial membrane permeabilization and cytochrome C release (Figure 3)
(Luo 1998).
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Extrinsic Apoptotic Pathway

Death ligand
Death receptor

FADD

Casp 8
Casp 8
Casp 8
Bid

Bad
tBid

Bax
Caspase 3

DNA fragmentation
Membrane blebbing

Chromatin condensation

Figure 3. Extrinsic Apoptotic Pathway. The extrinsic apoptotic pathway is
triggered by external signaling molecules or death ligands binding to death
receptors at the plasma membrane. This binding initiates the trimerization of the
receptor which in turn recruits the adapter molecule FADD to the cytosolic portion
of the receptor. Once bound, caspase 8 is recruited and activated via an induced
proximity self cleavage event. Activated caspase 8 then cleaves and activates
caspase 3 leading to completion of the apoptotic program or cleaves the proapoptotic Bcl-2 molecule Bid which then translocates to the mitochondria to
activate Bax or Bak which will cause disruption of the mitochondrial membrane.
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1.6 Intrinsic apoptotic pathway

The Intrinsic apoptotic pathway can be triggered by a multitude of signals
including but not limited to: ER stress, DNA damage, and depletion of nutrients.
These intrinsic apoptotic stimuli will set into motion intracellular signaling events
involving the Bcl-2 family of proteins that result in the disruption of the
mitochondrial membrane, followed by the release of cytochrome C.

The Bcl-2 family of proteins makes up a group of both anti-apoptotic
members and pro-apoptotic members. The anti-apoptotic members include Bcl-2,
Bcl-xL, Mcl1, and Bcl-w.

Pro-apoptotic members can be classified as either

multidomain, such as Bax and Bak, or as BH-3 only (Bcl-2 Homology domain 3
only) such as PUMA, Noxa, Bim and Bad (Figure 4). Proapototic members can
be regulated in a number of ways. For instance, regulation can occur by
phosphorylation (Bad) or increased expression in response to trophic factor
withdrawal (Bim and PUMA) or in response to genotoxic stress (PUMA, Noxa
and Bax) or by cleavage (Bid) in response to death ligand signaling. The primary
role of BH3 only members, such as PUMA, is to assist the proapoptotic functions
of Bax and Bak (Chao and Korsmeyer 1998, Scorrano and Korsmeyer 2003).
Interestingly, the BH-3 only proteins share only a 9 amino acid sequence
similarity found in the BH-3 region (Huang and Strasser 1997) and this region is
responsible for the pro-apoptotic function. Bax or Bak is necessary for the
release of cytochrome C whereas truncated Bid (tBid) (Fidzianska and Goebel
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1991), as well as distinct but yet unidentified pathway (Kandasamy et al. 2003),
is required for additional mitochondrial disruption.

Bcl-2 Family of Proteins
Bcl2, BclXL, Mcl1, CED9

Bax, Bak

BclXs
Bik, Bim
Bad, Bid, Egl-1, PUMA, Noxa

BH1
BH2

BH4
Transmembrane
domain

BH3

Figure 4. Bcl-2 family of proteins. This family of proteins is the watchdog of
apoptosis, guarding the mitochondrial membrane. Most members contain multiple BH
domains, however some contain only the BH-3 domain, which is responsible for the proapoptotic functions. Additionally, some members contain a transmembrane domain.
Although these proteins function mainly at the mitochondria, their cytosolic locations may
not be at the mitochondria when not activated.
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Hypotheses of upstream events leading to mitochondrial membrane disruption
vary but the general consensus is that Bax or Bak dimerization leads to the
formation of a mitochondrial permeability transition pore within the mitochondrial
membrane (Datta et al. 1997 and Lindsten et al. 2000). These pores cause the
membrane potential to become disrupted and to the release of cytochrome C as
well as other pro-apoptotic molecules (Scorrano 2002). Bax or Bak dimerization
is prevented by binding of Bax or Bak to the anti-apoptotic Bcl-2 or Bcl-XL
molecules. The mechanism responsible for the interruption of the Bcl-2/Bax or
Bak interaction is not fully understood, but activated Bid has been shown to play
a role (Letai 2002). Additionally, it is thought that PUMA, another pro-apoptotic
Bcl-2 member, may act at the mitochondria by binding Bcl-2 or Bcl-XL (Bouillet
and Strasser 2002). Once cytochrome has been released, formation of the
apoptosome occurs. The apoptosome consists of the cytosolic adapter protein
Apaf-1, ATP, cytochrome C and procaspase 9 (Acehan 2002). Upon formation
of the apoptosome, caspase 9, an initiator caspase, is activated, and once
activated, will in turn activate the executioner caspases 3, 6 and 7 (Figure 5)
(Slee 1999).

14

Intrinsic Apoptotic Pathway

DNA damage
ER stress

Nutrient depletion
Bak Bcl2

Bcl
Bcl22

Bak

Bcl2

Bax
Bcl2

Smac/Diablo

mitochondria

Activated
caspase 9

Bax

Bax

Caspase 9

Caspase 3

Caspase 9

Omi

IAP

Bak
BakBak

Bak
Bcl2
Bax

Chromatin condensation
DNA fragmentation

cytochrome C

Figure 5. Intrinsic Apoptotic Pathway. Upon apoptotic stimulus, such as DNA
damage, ER stress or nutrient depletion, signaling events key to the release proapoptotic molecules from the mitochondria. Cytochrome C binds Apaf-1 which
recruits caspase 9. This complex, the apoptosome, activates caspase 9 which in
turn activates caspase 3 via cleavage event. Smac/Diablo and Omi can also be
released, which function to block the anti-apoptotic IAPs that block caspase 3
activation. Once caspase 3 is activated, the final stage of apoptosis occurs as
seen by chromatin condensation and DNA fragmentation.
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1.7 Overview of mitochondrial disruption in other systems

Apoptosis in other systems is a result of the mitochondrial outer
membrane permeabilization (MOMP) followed by the release of pro-apoptotic
molecules

from the inner membrane space of the mitochondria (Newmeyer and

Ferguson-Miller 2003). These molecules include: cytochrome C, Smac/Diablo,
Omi, apoptosis inducing factor (AIF), and endonuclease G. Upon release from
the mitochondrion, cytochrome c, along with the cytosolic adaptor protein Apaf-1,
forms the apoptosome to activate caspase 9, an initiator caspase. A caspase
(cysteine-aspartic acid specific protease) cascade is initiated by the release of
cytochrome C from the mitochondria (Robertson et al. 2000, Salvensen and Dixit
1997, Thornberry and Lazebnik 1998). Smac/Diablo acts as antagonist through
an inhibitory binding of cytosolic inhibitor of apoptosis proteins (IAPs) to enhance
this cascade when released, whereas Omi is responsible for cleavage of IAPs.
The function of IAPs is to bind and inhibit the activation sites of caspase 3, 7 and
9 and target these for proteosomal degradation. A non-canonical form of
apoptosis that is caspase-independent results from the release of apoptosis
inducing factor (AIF) and endonuclease G from the mitochondrial inner
membrane space (19), in addition to the loss of the mitochondrial membrane
potential (#$m) (Kroemer 1999). AIF and endonuclease G both can lead to DNA
fragmentation and chromatin condensation in the absence of caspase activation.
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1.8 Caspases

Caspases (cysteine aspartic acid-specific proteases) are proteases which
are expresses as inactive zymogens or pro-caspases. Caspases can be
classified as initiator caspases, which include caspases 2, 8 9 and 10, or
executioner caspases, which include caspase 3, 6 and 7. The role of the initiator
caspases is to activate the downstream executioner caspases. The role of
executioner caspases is to carry out the degradation of cellular components
including structural proteins and DNA, resulting in membrane blebbing and final
clearance (Salvesan et al. 1997 and Savill and Fadok 2000). Structurally,
caspases contain a prodomain, and the catalytic caspase domain. The caspase
domain is subdivided into large and small subunits. Inactive caspases occur as
homodimers, but upon cleavage, associate into a tetrameric complex containing
two large and two small subunits (Figure 5). Caspases contain a cysteine residue
within the catalytic pocket that participates in the cleavage of the carbonyl end of
aspartic acid residues found within target proteins.
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prodomain
prodomain

small
small

large
large

Inactive
homodimer

Catalytic domain
large

prodomain
large

small
small

Active tetrameric
complex

Figure 6. Caspase structure and activation. Caspases are expressed in an
inactive form and exist in the cytosol as homodimers. Once an apoptotic signal is
received, the procaspase domain is cleaved followed by the formation of the now active
tetrameric complex. The large and small domains make up the catalytic subunit
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1.9 Serine Proteases in apoptosis

Serine proteases have been implicated in the apoptotic process.
Granzyme B, which is a serine protease expressed in T cells also contributes to
apoptosis (Talanian et al. 1997). Interestingly, in melanoma cells, serine
proteases were found to participate in apoptosis in a caspase independent
manner. Omi is known to be released from the mitochondria during apoptosis
and functions to cleave IAPs (Miller and Stockdale 1986). Omi is expressed in an
inactive form and is activated via autocatalytic process. Once activated, Omi
translocates to the cytosol where it binds XIAP (x linked inhibitor of apoptosis)
protein (Hedge et al. 2002). The protease function of Omi has not yet been found
(Verhagen et al.2002). Utilizing the serine protease inhibitor AEBSF, apoptosis
was abrogated upon DNA damage, induced by etoposide and ER stress induced
by tunicamycin or brefeldin A (de Bruin et al. 2003). Additionally, blocking
caspase activation by treatment with z-VDVAD-fmk, a cell permeable caspase
inhibitor that binds to the active site but cannot be cleaved, was unable to inhibit
DNA damage or ER stress induced apoptosis. Similar results were also seen in
rat fibroblasts, thymocytes, HeLa and neuronal cells (Egger et al. 2003). In the
rat fibroblast, over-expression of Bcl-2 was able to block this caspase
independent apoptosis (Egger et al. 2003). The mechanism, by which serine
proteases can perpetuate apoptosis, is unknown. We have determined that
AEBSF blocks the release of cytochrome C in skeletal myoblasts cultured in DM.
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A serine protease that functions prior to mitochondrial disruption has not yet been
reported.

1.10 Molecular mechanisms of apoptosis in skeletal myoblasts

Upon induction of differentiation in skeletal myoblasts, apoptosis occurs in
vertebrate model systems, in primary cultured myoblast systems and in
established cell lines, such as C2C12 myoblasts and 23A2 myoblasts (Dee et al.
2002, Wang and Walsh 1996, Fidzianska and Goebel 1991, and Sandri et al.
1996). Our lab has previously reported that when cultured myoblasts are
switched

from

growth

medium

(GM)

to

differentiation

medium

(DM),

approximately 30% of myoblasts will undergo to apoptosis, whereas the
remaining 70% will exit the cell cycle and differentiate. The apoptotic process will
occur within 12 hours while the differentiation process takes 48 hours (Dee et al.
2002). Typically, myoblasts will first exit the cell cycle, and then proceed to
differentiation. Differentiation results in survival (Wang and Walsh 1996, Miller
and Stockdale 1986).

Our lab has documented a role for PUMA, the TRAIL/DR5/FLIP pathway,
serine proteases, release of cytochrome C and activation of caspase 9 and 3 in
the apoptotic process of skeletal myoblast induced to differentiate. While
regulation of PUMA (Nakanishi and Morishima 2005, Nakano and Vousden 2001,
Yu et al. 2001), DR5 (Han et al. 2001) and FLIP (Wu et al. 1997) is attributed to
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p53 in other systems, we have found that increased PUMA expression is not a
result of p53 signaling in skeletal myoblasts. DR5 and FLIP regulation have not
yet been investigated. The transcription factor FOXO3a also regulates PUMA
and FLIP (Cerone et al. 2000, You et al. 2006). However, activation of FOXO3a
is responsible for the increased expression of proapoptotic member Bim and
TRAIL, but this does not occur in our system (Skurk et al. 2004, Wang et al.
2002). We have previously documented cells that express constitutively active
forms of G12V H-Ras and Raf will not undergo differentiation and are defective
for apoptosis in response to serum withdrawal (Dee et al. 2002, Wang et al.
1997). Thus our data suggests expression of G12V H-Ras leads to a decrease in
the expression of MyoD.

1.11 Transcription factors associated with apoptosis

MyoD induces differentiation, but can it also play a role in apoptosis?
Transcription factors associated with the expression of proapoptotic molecules
include p53 (Scorrano 2003), FOXO3a (Cerone et al. 2000, You et al. 2006,
Gilley et al. 2003 and Wildey and Howe 2009), STAT1 (Peschiaroli et al. 2002),
SMAD3 (Kumar et al. 1997) and Myc (Wildey et al. 2003). Of these, MyoD
activity most closely resembles that of either p53 or FOXO3a.
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1.11.1 P53
The well known, intensely studied tumor suppressor p53 has been
reported to have an impressive number of roles including regulation of
metabolism, proliferation, differentiation and apoptosis. Since this body of work
encompasses the study of apoptosis and to some degree, proliferation and
differentiation, we will discuss only these functions of p53. One mechanism by
which p53 can induce cell death is by the expression of the pro-apoptotic Bcl-2
member PUMA (Nakano et al 2001). Additionally, p53 plays a role in regulation
of cell cycle progression. The cyclin dependent kinase inhibitor p21 has been
shown to be activated by p53 (el-Diery 1998). Cell cycle and apoptotic regulation
by p53 serves dual purposes. Firstly, exit from cell cycle can allow sufficient time
to correct any harm caused by genotoxic stress, preventing tumor formation
(Gatz and Wiesmuller 2006). Secondly, exit from the cell cycle or apoptosis
blocks progression of tumor growth.

Interestingly, p53 has been shown to play a role in myoblast
differentiation rather than apoptosis. When cultured in DM,

p53-/- myoblasts

showed a 50% reduction in differentiation as detected by the expression of
myosin heavy chain in comparison to p53+/+ myoblasts (Porrello et al. 2000).
This differentiation defective phenotype was attributed to the failure to upregulate
Rb, since expression of MyoD, myogenin, p21, cyclinD1, and cyclinD3 showed
no changes in expression patterns (Porrello et al. 2000). The role of Rb during
differentiation is to induce cell cycle withdrawal and it cooperates in regulating
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the expression of late differentiation genes (Gu et al. 1993). Also shown in the
previous paper was that p53-/- myoblasts, when cultured in DM, differentiation
associated apoptosis levels did not change, supporting our findings that
apoptosis in skeletal myoblasts cultured in DM is a non-p53 mediated event
(Shaltouki et al. 2007).

1.11.2 FOXO3a

Foxo3A is another transcription factor that serves dual roles in cells.
Under certain stress conditions, Foxo3a can regulate apoptosis or cell cycle
progression. One way Foxo3a can regulate apoptosis is through the increased
expression of the pro-apoptotic Bcl-2 member Bim. Bim pro-apoptotic function is
exerted in cells by binding the anti-apoptotic protein Bcl-2. Bcl-2 functions to
inhibit apoptosis by preventing the dimerization of Bax or Bak, a step that is
critical for the release of cytochrome C during mitochondrial apoptosis. Other
pro-apoptotic target genes for Foxo3a are TRAIL and FasL (Obexer et al. 2007).
Both FasL and TRAIL are responsible for the activation of the extrinsic apoptotic
pathway by binding their respective death receptors Fas and DR5. Foxo3a can
also block cell cycle progression by regulating the expression of GADD45 or p21
(Tran et al. 2002). As with p53, expression of cell cycle inhibitors can allow cells
with genotoxic DNA damage to repair the damage, rather than undergo
apoptosis, thus promoting survival rather than cell death.
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MyoD is a helix loop helix transcription factor. To date, the only other helix
loop helix transcription factors known to be involved in the apoptotic process is
the Daughterless-like (HLH-2) and Achaete-scute-like (HLH-3) transcription
factors expressed in C. elegans, shown to induce apoptosis during neuronal
development (Thellmann et al. 2003). Additionally, preliminary evidence using
RNAi (RNA interference) in C. elegans has suggested that HLH-2, along with
HLH-3, regulates the expression of egl-1, a BH3 only protein similar to PUMA
(Peden et al. 2008).

The role of MyoD in skeletal myoblast differentiation has been extensively
studied. However, the potential role of MyoD in skeletal myoblast apoptosis is a
novel idea. The purpose of this body of work is to explore the role of MyoD in
regulation of the apoptosis associated with differentiation as well as in response
to other more traditional apoptotic stimuli. Further, we will explore the molecular
mechanisms by which MyoD can affect apoptosis. My first hypothesis is that
MyoD is sufficient and necessary for the differentiation-associated apoptosis in
response to culture in DM in both skeletal myoblasts and in fibroblasts. My
second hypothesis is that MyoD plays a role in apoptosis in response to the DNA
damaging agent etoposide and thapsigargin, an agent which induces ER stress.
Lastly, my third hypothesis is that MyoD plays a role in the expression of the proapoptotic Bcl-2 protein PUMA in response to culture in DM and in response to
etoposide and thapsigargin treatments in GM.
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CHAPTER II
MATERIALS AND METHODS

2.1 Cells and cell culture

The growth and differentiation properties of 23A2 myoblasts and the 23A2
derivatives expressing the G12V:H-Ras (A2:H Ras myoblasts), A2Q61K N-Ras
(N-Ras) (Weyman and Wolfman, 1997), 10T1/2 (Weyman et al. 1988) and
10T1/2 ER:MyoD fibroblasts (Hollenberg et al. 1993) have been reported
previously.

Cells were cultured on gelatin-coated plates and maintained in

growth medium (GM), which consists of basal modified Eagle’s medium (BME),
10% fetal bovine serum (FBS) and a 1% combination of 10,000 I.U./ml penicillin
and 10,000 %g/ml streptomycin (1% P/S).

Differentiation was induced by

switching cells from growth medium to differentiation medium (DM), which
consists of BME, 1% P/S and 0% FBS. Cells were incubated at 37&C in 5% CO2.
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2.2 Transient Transfection
Prior to transfection, cells were plated at 1 X 105 on 35 mm 6 well culture dishes
or at 4X105 on 100 mm culture plates. A plasmid containing the full length cDNA
of murine MyoD (pcDNA3:MyoD) was transfected using Lipofectamine and Plus
reagents following manufacturers’ instructions (GibcoBRL).

Briefly, varying

amounts as indicated of plasmid DNA was preincubated with Plus reagent in
OPTImem low serum media, then combined with Lipofectamine preincubated
with OPTImem for 15 minutes. Cells were washed with phosphate buffered
saline 7.4 (PBS) followed by the addition of plasmid DNA/Lipofectamine/Plus
reagent mixture to the cell culture.

After three hours, the OPTImem

DNA/Lipofectamine/PLUS mixture was replaced with fresh GM and cells were
allowed to incubate overnight.

2.3 Immunoblot analysis

Cells were plated at 4 X 105 and the following day, were treated as indicated in
each figure legend. Lysates were prepared by adding 50-100 %l of lysis buffer
(20 mM MOPS pH 7.4, 5 mM magnesium chloride, 200 mM sucrose, 100 mM
EDTA, 0.001% DNAse, 200 mM P-ser ,

100 mM P-tyr, 100 mM P-thr , 100

mM PNPP, 1 M phenyl methylsufonylfluoride (PMSF) and 50 %g/ml each of
aprotinin, pepstatin, and leupeptin with 1% CHAPS). Protein concentrations of
the cell lysates were determined using Coomassie Protein Assay reagent from
Pierce per manufacturer’s instructions. Following protein determination, lysates
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were denatured in 5X sample buffer containing 10% SDS, 50% glycerol, 10% 2mercaptoethanol, 300 mM Tris HCl, and pH 6.8 and 0.0025% bromphenol blue.

Protein extracts were separated through denaturing polyacrylamide gels
following the Laemmli method (Laemmli 1970). Following SDS polyacrylamide
gel electrophoresis (SDS-PAGE), samples were transferred electrophoretically
from thirty-five minutes to one hour at 1500 milliamps onto Hybond-P
polyvinylidene difluoride membrane in transfer buffer (20% methanol, 1 g/L SDS,
5.8 g/L Tris base and 29 g/L glycine. After transfer, membranes were placed in a
blocking solution of 5% non-fat dry milk, 10% newborn calf serum in TBS-T buffer
(136.9 mM NaCl, 25 %M Tris and 1% Tween20).

Immunoblot analysis was

performed to detect: p53 by incubating membrane for 1 hour with p53 antibody
diluted 1:1000 , MHC

by incubating membrane for one hour with a mouse

monoclonal antibody MF20 that is specific for skeletal myosin heavy chain
protein (Bader et al. 1982), MyoD by incubating membrane overnight with a
mouse monoclonal MyoD antibody (BD Biosciences, 554130) diluted 1:1000,
PUMA by incubating membrane overnight with a rabbit polyclonal PUMA
antibody (Abcam ab-9643) diluted 1:500. Actin or Hsp70 expression levels were
monitored to ensure equal loading using monoclonal anti-! actin antibody (Sigma
A5441- 0.5ML) diluted 1:30,000 or anti-Hsp70 antibody (BD Biosciences
610608). All membranes were then incubated in an HRP-conjugated secondary
antibody to the primary antibody for one hour diluted 1:1000. Following
incubation with antibodies and prior to the addition of chemiluminescence
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substrate, the membranes were washed 5 times in TBS-T buffer. Membranes
were then incubated with SuperSignal West Pico Chemiluminescence Substrate
(Pierce) as instructed by the manufacturer and bands were visualized by using
Kodak Scientific Imaging film.

2.4 ELISA

The presence of cytosolic nucleosomes is a hallmark of apoptosis and indicates
that DNA fragmentation has occurred. Cytosolic nucleosomes were detected
using the Cell Death Detector ELISA (Enzyme linked immunosorbant assay) plus
kit (Roche Diagnostics). Briefly, G12V H-Ras myoblasts or 23A2 myoblasts were
plated 105 per well in 6 well plate. Next day, G12V H-Ras myoblasts were
transfected as described in figure legend and next day transferred to culture in
GM or DM for 8 hours as noted. Cells were lysed in 100 %l lysis buffer from Cell
Death Detection ELISA kit for 30 minutes with rocking at room temperature. The
contents of this lysis buffer are unknown (proprietary according to Roche). This
lysis buffer only breaks plasma membrane and leaves nuclear membrane intact.
Cytosolic extracts were then incubated in 96-well microtiter plate pre-coated with
streptavidin. Additionally, a mater mixture containing 72 %l incubation buffer and
4 %l each histone:biotin antibody and DNA:ABTS antibody was added to each
well The lysate/antibody mixture was incubated at 4ºC rocking overnight. Next
day, plate was washed three times with PBS, followed by addition of 100 %l
ABTS substrate prior to reading on plate reader at 405 nm wavelength at 60
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second intervals for 30 minutes. Readings were taken at a time point when in
linear range.

2.5 Stable transfection of shRNA for gene knockdown
2.5.1 Assembly of lentiviral vector for transduction of myoblasts

We purchased a pKLO.1 vector expressing a shRNA against murine MyoD or no
insert. These expression vectors were transformed in DH5! E. coli, then grown
up on agar plates containing the selective antibiotic carbenicillin (Sigma C1389).
The expression vector was grown in broth culture and purified using Qiagen
Midiprep kit.

Next, lentivirus was assembled using HEK293Tcells. 293T cells were transfected
with pKLO.1 shRNA vectors along with pCMVdelta 8.2 lentivirus vector and
pVSV-G vector expressing viral coat protein. Briefly, 2 million cells were plated
on 60mm plate. Next day, media was removed and washed with PBS, followed
by transfection with solution containing 300 %l OPTImem, 12 %l Lipfectamine
2000 and 5 %g each pKLO.1, pCMV#R8.2 and pVSV-G vectors for 10 hours.
After 10 hours transfection reagent was removed and 4 ml DMEM containing
10% FBS and 1% penstrep was added. After 24 hours, media containing the
assembled shMyoD expressing lentivirus or empty vector was collected, and
again fresh DMEM was added. This was repeated for three days. The collected
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DMEM was centrifuged to remove cellular debris then flash frozen at -80ºC for
future use.

2.5.2 Stable transduction of myoblasts with lentivirus containing pKLO.1
puro-MyoD shRNA or pKLO.1 puro (control vector)

23A2 or C2C12 myoblasts were plated at 400,000 cells per plate and next day
transduced with lentivirus. Briefly, 23A2 myoblasts and C2C12 myoblasts were
cultured in previously frozen DMEM containing lentivirus plus 10ug/ml polybrene
overnight. Next day, DMEM was removed and replaced with fresh GM for 24
hours. Next day, cells were split into 3 150 mm plates and cultured in GM
overnight. Next day, cells were cultured in GM plus puromycin (2ug/ml Sigma
P8833) for two weeks. After two weeks, clonal populations were selected for
further analysis of MyoD expression by immunoblot analysis and RT-PCR.

2.6 Semi-quantitative RT- PCR

Cells were plated at 4x105 /100 mm plate and cultured in GM overnight. Next day
cells were cultured as indicated in figure legends. Total RNA was isolated using
standard Trizol (Invitrogen) procedures as indicated by manufacturer. Following
extraction and quantitation of RNA, 0.5-1ug of total RNA was used in a 20 %l
reverse transcription reaction using superscript III (Invitrogen) as indicated in
manufacturers instructions with dNTPs, random hexamers, DTT and 5X
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manufacturer buffer. 2 %l of the cDNA was used in real time PCR reaction with
forward and reverse primers and 10 %l of Platinum® SYBR®Green qPCR
SuperMix (Invitrogen). Reactions were performed in triplicate, amplified and
quantified using the Opticon 2 quantitative real time PCR system (MJ Research).
The cycle number at which fluorescence increased linearly was calculated by the
Opticon monitor in the form of Ct values. The Ct value for GAPDH (used as a
control reaction) was subtracted from the GAPDH value for the untreated control
(GM, vehicle control, etc.) to obtain the correction factor (#Ct

(GAPDH)).

This

correction factor was then subtracted from the Ct value for each experimental
mRNA (mexp): (Ct(mexp)- #Ct (GAPDH)= normalized Ct(mexp). The normalized value for
each experimental mRNA was then subtracted from the value of the
corresponding untreated control to obtain the difference in cycle number. The
difference of a single cycle is the equivalent to a 200 percent change in mRNA,
so that the normalized value of each experiment is expressed as a change over
the untreated sample (set to 100%)

2.7 RT-PCR

Reverse transcription is the same as described above. The PCR reaction differs
as follows. Again 2 %l of the cDNA was used in the PCR reaction along with
forward and reverse primers plus 10ul of 2X PCR mix (Fermentas). PCR
reactions were run for the number of cycles in which amplification of products
were still within a linear range as determined by previous reactions. PCR
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products were then run on 1% agarose gel stained with ethidium bromide.
Images were analyzed using GE Healthcare Life Sciences Typhoon 9410 Imager
and band volume quantified using ImageQuant software (v5.2).
Table 1: Primers for PCR

Message

Forward Primer

Reverse Primer

MyoD

GACAGGACAGGACAGGGAGG

GCACCGCAGTAGAGAAGTGT

PUMA

CCAGAAATGGAGCCCAACTA

TATGCTCTTCACAGACCCCC

GAPDH

TGATGACATCAAGAAGGTGGTGAAG

TCCTTGGAGGCCATGTAGGCCAT
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CHAPTER III
RESULTS

3.1 MyoD regulates the apoptosis associated with differentiation

Our lab has shown that switching cultured 23A2 skeletal myoblasts from
GM (growth medium) to DM (differentiation medium) induces approximately 30%
of cells to undergo apoptosis (DeChant et al. 2002). Our laboratory (Karasarides
et al. 2006) and others (Konieczny et al. 1989) have previously shown that
skeletal myoblasts expressing oncogenic G12V:H-Ras cause 23A2 myoblasts to
become differentiation defective. Additionally, in myoblasts expressing oncogenic
G12V H-Ras, levels of both MyoD mRNA and protein are below the level of
detection (Konieczny et al. 1989, Karasarides et al. 2006). Re-expression of
MyoD in myoblasts expressing G12V:H-Ras can restore differentiation
(Koniecnzy et al. 1989). Our lab has recently reported that the apoptotic potential
of skeletal myoblasts correlates with expression levels of MyoD (Karasarides et
al. 2006). These findings have lead us to hypothesize that MyoD may play a
critical role in both the ability to undergo apoptosis or differentiation as a result of
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serum withdrawal. To test this hypothesis, we utilized 23A2 skeletal myoblasts
stably transfected with oncogenic G12V:H-Ras or Q61K:N-Ras. In the 23A2
myoblasts expressing G12V H-Ras, MyoD expression is below the levels of
detection, whereas MyoD expression in Q61K:N-Ras expressing myoblasts is
reduced as compared to mock transfected myoblasts (Figure 7). 10T1/2
fibroblasts which do not express MyoD are included as a negative control.
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Figure 7. MyoD expression is reduced in oncogenic Ras expressing
skeletal myoblasts. Equal numbers of cells were plated and next day, in (A). whole
cell lysates were collected, separated by SDS-PAGE prior to electrophoretic transfer to
PVDF membrane and immunoblot analysis for MyoD. Shown are results from one
experiment that are representative of 2 independent experiments. In (B) total cellular
RNA was isolated using standard Trizol method followed by reverse transcription. DNA
was subjected to PCR analysis using Alexa Fluor 647 labeled primers for MyoD and
actin. In (C) images from B were analyzed using GE Healthcare Life Sciences Typhoon
9410 Imager and band volume quantified using ImageQuant software (v5.2). Shown are
results from one experiment that are representative of 2 independent experiments.
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In order to measure apoptosis in different oncogenic Ras expressing cell
lines, we cultured equal number of cells with DM for 18 hours followed by
counting detached cells and total number of cells. Myoblasts undergoing
apoptosis will become detached from the tissue culture plate whereas cells which
are either quiescent or undergoing differentiation will remain adherent (Dee et al.
2002). The myoblasts expressing different oncogenic Ras isoforms exhibit
reduced apoptotic potential as compared to the parental 23A2 myoblast (Figure
8).
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Figure 8. Oncogenic Ras-expressing myoblasts have reduced apoptotic
potential. Equal numbers of cells were plated and next day switched to DM for 18
hours. DM was collected and floating cells were counted. Cells remaining on the tissue
culture plate were counted. Percent apoptotic cells were calculated by taking detached
cells divided by total cells (adherent + detached). Shown is an average of triplicates
(mean +/- standard deviation) from one experiment that is representative of three
independent experiments.
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To further support our hypothesis that MyoD plays a role in apoptosis, we
transiently re-expressed ectopic MyoD in oncogenic G12V:H-Ras expressing
myoblasts at levels comparable to the endogenous levels found in parental 23A2
myoblasts. We decided to use this oncogenic Ras expressing myoblast cell line
since endogenous levels of MyoD expression were below the levels of detection,
making ectopic expression of MyoD easy to distinguish from any endogenous
MyoD expression present. Both differentiation and apoptosis are induced by
culture in differentiation medium (DM). This media contains low or no serum and
mimics the decreased gradient of growth factors which myoblasts encounter as
they migrate away from the notochord during embryonic development (Olson
1992). The next day after transient transfection, we then cultured myoblasts in
DM for 24 hours and assayed for the expression of MHC as a marker for
differentiation. We performed immunoblot analysis on oncogenic H-Ras
expressing myoblasts expressing ectopic MyoD and found that differentiation
was restored as evidenced by the expression of MHC (Figure 9).

37

B

DM (48 hours)

MHC
actin
pcMyoD
(ng)

0
23A2

0

100 250 500 1000
A2: G12V H-Ras

Figure 9. Transient ectopic expression of MyoD in G12V H-Ras myoblasts
is sufficient to restore differentiation. Equal numbers of cells were plate and next
day transiently transfected with the indicated amount of plasmid for 3 hours prior to
switching to GM for 24 hours. In (A) whole cell lysates were collected then separated by
SDS-PAGE and followed by immunoblot analysis for MyoD expression. Actin was
monitored for equal loading. In (B) cells were cultured in DM for 24 hours followed by
collection of whole cell lysates which were then separated by SDS-PAGE prior to
electrophoretic transfer to PVDF membrane and immunoblot analysis for MHC
expression. Actin was monitored for equal loading. Shown are results from one
experiment that are representative of two independent experiments.
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As the process of transient transfection can induce cytosolic nucleosome
formation, we were required to wait 24 hour post transfection before beginning
any apoptosis studies which involved the detection of apoptosis by measuring
cytosolic nucleosomes. We previously determined that the optimum time for the
detection of cytosolic nucleosomes in parental 23A2 myoblasts was after eight
hours of culture in DM. We compared the level of cytosolic nucleosomes using
the ELISA kit (enzyme linked immunosorbant assay) (Roche) that utilizes an
antibody directed against cytosolic histones and an antibody against DNA
conjugated with peroxidase, which when activated in the presence of ABTS,
results in a colorimetric change that that can be quantitative. Myoblasts
undergoing apoptosis will contain DNA/histone fragments in the cytosol. Only
cytosolic lysates are used in this assay. We found that ectopic expression of
MyoD in oncogenic H-Ras expressing myoblasts restores their apoptotic
potential (Figure 10). Thus, MyoD confers the ability to undergo both
differentiation and the associated apoptosis.
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Figure 10. Ectopic expression of MyoD in G12V H-Ras expressing
myoblasts restores apoptotic potential in response to serum withdrawal.
Equal numbers of cells were plated and next day transiently transfected with the
indicated amount of plasmid as indicated for 3 hours prior to switching to GM for 24
hours. Cells were treated with fresh GM or DM as indicated for 8 hours. DNA
fragmentation was assayed using the Cell Death Detection ELISAPLUS kit. Shown is an
average of triplicates (mean +/- standard deviation) from one experiment that is
representative of three independent experiments.
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Next, we determined if MyoD expression could induce apoptosis in
fibroblasts in response to serum withdrawal by culture in DM. We utilized 10T1/2
fibroblasts that stably express an inducible estrogen receptor: MyoD fusion
protein (ER-MyoD:10T1/2)

to perform the next set of experiments. The ER-

MyoD fusion protein is expressed but cannot induce transcription unless treated
first with estradiol. When estradiol is added to the culture medium, this allows
ER-MyoD fusion protein to translocate to the nucleus. We assessed the ability of
these fibroblasts to undergo differentiation as evidenced by the expression of
myosin heavy chain. This was included as a control to show that the ER-MyoD
fusion protein could induce differentiation. Immunoblot analysis shows when
cultured in DM with estradiol, these fibroblasts express myosin heavy chain
(Figure 11A). To determine the apoptotic potential, fibroblasts were cultured in
DM for 24 hours with or without estradiol. In the absence of estradiol, the ERMyoD:10T1/2 fibroblasts contained no more cytosolic nucleosomes than the
parental 10T1/2 fibroblasts cultured in DM. However, the apoptotic potential was
increased seven fold in ER-MyoD: 10T1/2 fibroblasts cultured in DM plus
estradiol as compared to the parental 10T1/2 fibroblasts cultured in DM plus
estradiol (Figure 11B). We also compared the expression of MyoD protein when
cultured in GM as well as MHC when cultured in DM between 23A2 and C2C12
myoblasts, 10T1/2 and ER-MyoD10T1/2 fibroblasts +/- estradiol as noted. MyoD
levels between each cell line correlated to the expression of MHC (Figure 12).
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Figure 11. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein sensitizes to the induction of differentiation
or the associated apoptosis in response to serum withdrawal. In (A) parental
10T1/2 fibroblasts or ER-MyoD:10T1/2 fibroblasts were cultured in DM 48 hrs +/estradiol prior to collection of whole cell lysates. Immunoblot analysis for myosin heavy
chain (MHC) expression was performed using 100 %g of total protein. Actin was
monitored for equal loading. Shown are results from one experiment that are
representative of 2 independent experiments. In (B) 10T1/2 or ER-MyoD:10T1/2
fibroblasts were cultured in DM +/- estradiol for 8 hours prior to analysis of DNA
fragmentation using the Cell Death ELISAplus kit. Shown is an average of triplicates
(mean +/- standard deviation) from one experiment that is representative of three
independent experiments.
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Figure 12. MyoD protein expression correlates with MHC expression
between cell lines utilized. Equal numbers of cells were plated. Immunoblot
analysis was performed for the expression of (A) MyoD or (B) MHC between all
cell lines as noted in (A) GM or (B) DM for various times, using 100 %g whole cell
lysates separated by SDS-PAGE prior to electrophoretic transfer to PVDF
membrane. Shown are results from one experiment that are representative of 2
independent experiments.
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Having determined that expression of MyoD plays a role in the ability of
myoblasts and fibroblasts to undergo apoptosis, in addition to its well known role
in differentiation, we next hypothesized that absence of MyoD in skeletal
myoblasts would render these cells defective for both differentiation and the
associated apoptosis. To test this hypothesis, we utilized RNAi technology. We
transduced 23A2 and C2C12 myoblasts with a lentivirus carrying a pKLO.1 puromurine MyoD specific short hairpin RNA (shRNA) or control vector pKLO.1 puro
and selected using the antibiotic puromycin for two weeks. After the selection
period, we selected clonal populations to analyze for the knock down of MyoD
expression. MyoD expression in untreated parental 23A2 or C2C12 myoblasts
(each designated as “P”), or a vector alone transduced 23A2 or C2C12
myoblasts clone (each designated as “C”) as well as multiple clones was
analyzed (23A2:shMyoD clones or C2C12:shMyoD clones). Monitoring MyoD
expression by both immunoblot analysis and qRT-PCR, we were able to
successfully knock down MyoD to varying degrees in 23A2 myoblasts and in
C2C12 myoblasts using the shRNA directed against murine MyoD (Open
Biosystems) (Figures 13 and 14). Having determining the expression level of
MyoD, we selected clones 23A2:shMyoD 13, 15 and 16 and C2C12:shMyoD 16,
17 and 19, for further analysis.
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Figure 13. Lentiviral transduction of shRNA against MyoD reduces the
expression of MyoD in 23A2 myoblasts. 23A2 myoblasts were transduced with
shRNA against MyoD and various clones were screened for the reduction in MyoD
expression levels. In (A) equal numbers of cells were plated and the next day total
cellular RNA was isolated using the standard TRIZOL method. Quantitative RT-PCR
was performed using the Quantitech Sybr Green PCR kit (Qiagen). Fluorescence was
detected using an Opticon Monitor (MJ Research) Opticon software was used to
calculate cycle threshold (Ct) values. The Ct value for MyoD PCR product was
normalized to the Ct value for actin PCR product run parallel. Shown is an average of
triplicates (mean +/- standard deviation) from one experiment that is representative of
three independent experiments. In (B) equal numbers of cells were plated. Immunoblot
analysis of MyoD protein expression was performed. Actin was monitored for equal
loading. Shown is the result from one experiment that is representative of three
independent experiments.
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Lentiviral transduction of shRNA against MyoD reduces the

expression of MyoD in C2C12 myoblasts. C2C12 myoblasts were transduced with
shRNA against MyoD and various clones were screened for the reduction in MyoD
expression levels. In (A) equal numbers of cells were plated and the next day total
cellular RNA was isolated using the standard TRIZOL method. RT-PCR was performed
for analysis of MyoD mRNA expression. PCR product was separated on an ethidium
bromide stained agarose gel. Images were analyzed using GE Healthcare Life Sciences
Typhoon 9410 Imager and band volume quantified using ImageQuant software (v5.2).
Shown is an average of triplicates (mean +/- standard deviation) from one experiment
that is representative of three independent experiments. In (B) an equal numbers of cells
were plated. Immunoblot analysis of MyoD protein expression was performed. Actin
was monitored for equal loading. Shown are results from one experiment that are
representative of 2 independent experiments.
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As a control, these clones were assessed for their ability to undergo
differentiation. We hypothesized that myoblasts will be rendered differentiation
defective in the absence of MyoD expression. We assayed the ability of these
myoblasts to undergo differentiation as evidenced by the expression of myosin
heavy chain after culture in DM for 48 hours. As anticipated, immunoblot
analyses shows both that the 23A2:shMyoD clones and the C2C12:shMyoD
clones with reduced MyoD expression fail to undergo differentiation when
cultured in DM (Figure 15). Finally, we also monitored these clones for their
ability to undergo apoptosis in response to culture in DM. As predicted,
23A2:shMyoD and C2C12:shMyoD myoblasts with reduced MyoD expression
were resistant to the induction of apoptosis, in response to culture in DM (Figure
16).
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Figure 15. Stable silencing of MyoD expression in 23A2 and C2C12 skeletal
myoblasts represses differentiation. Equal numbers of cells were plated and next
day cultured in DM for 48 hours. Whole cell lysates were collected then 100 %g of total
protein was separated by SDS-PAGE prior to electrophoretic transfer to PVDF
membrane and immunoblot analysis for MHC expression in (A) 23A2 myoblasts
parental, control and shMyoD clones and MHC expression in (B) C2C12 myoblasts
parental, control and shMyoD clones. Actin was monitored for equal loading. Shown is
the result of one experiment that is representative of three independent experiments.
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Figure 16. Stable silencing of MyoD expression in skeletal myoblasts
represses apoptosis as a consequence of serum withdrawal. Equal numbers
of cells were plated and next day switched to fresh GM or DM for 24 hours. In (A), 23A2
myoblast parental, vector, and shMyoD clones and in (B) C2C12 myoblast parental,
vector and shMyoD clones, next day, detached cells and adherent cells were collected
and then counted. Percent apoptosis was calculated (number of detached cells/
detached cells plus adherent cells). Shown is an average of triplicates (mean +/standard deviation) from one experiment that is representative of three independent
experiments.
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3.2 MyoD regulates apoptosis in response to other apoptotic stimuli

Since we have determined that MyoD plays a role in the apoptosis
associated with differentiation and since this can also be considered as apoptosis
induced in response to serum withdrawal, we next hypothesized that MyoD might
regulate apoptosis in response to other apoptotic stimuli. We next wanted to
analyze apoptosis in response to DNA damage or ER stress.

Prior to testing this hypothesis, we performed time and concentration
course analysis for the treatment with etoposide, an agent that induces doubleand single-strand breaks in DNA in intact cells or thapsigargin, a compound that
causes the release of stored calcium from the ER and blocks calcium re-uptake,
leading to toxic intracellular levels. We determined that the optimum time and
concentration for treatment to easily detect apoptotic cells with etoposide was
200 %M for 24 hours and with thapsigargin it was 3 %M for 24 hours (Data not
shown). We then assessed the effect of MyoD expression in myoblasts on the
apoptosis induced by etoposide or thapsigargin. As predicted by the previous
experiments, etoposide and thapsigargin each induced apoptosis in the 23A2
and C2C12 parental (P) or empty vector transduced (C) myoblasts. As
hypothesized, the 23A2:shMyoD and C2C12:shMyoD clones, where MyoD
expression was reduced, were resistant to the induction of apoptosis induced by
etoposide or thapsigargin (Figures 17 and 18 respectively).
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Figure 17. MyoD expression enhances apoptosis induced by agents which
cause DNA damage. Equal numbers of cells were plated and next day treated with
vehicle (DMSO) or 200 uM etoposide in GM for 24 hours. In (A), 23A2 myoblast
parental, vector and shMyoD clones and in (B) C2C12 myoblast parental, vector and
shMyoD clones, next day, detached cells and adherent cells were collected, then
counted. Percent apoptosis was calculated (number of detached cells/ detached cells +
adherent cells). Shown is an average of triplicates (mean +/- standard deviation) from
one experiment that is representative of three independent experiments.
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Figure 18. MyoD expression enhances apoptosis induced by agents which
cause ER-stress. Equal numbers of cells were plated and treated with vehicle or 3%M
thapsigargin for 24 hours. In (A), 23A2 myoblast parental, vector and shMyoD clones
and in (B) C2C12 myoblast parental, vector and shMyoD clones, next day, detached
cells and adherent cells were counted and percent apoptosis was calculated (number of
detached cells/ detached cells plus adherent cells). Shown is an average of triplicates
(mean +/- standard deviation) from one experiment that is representative of three
independent experiments.
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We next assessed the effect of MyoD in fibroblasts on the apoptosis
induced by etoposide or thapsigargin treatment. Using the same conditions as
previously described for the myoblasts, we treated 10T1/2 fibroblasts and
ER:MyoD 10T1/2 fibroblasts for 24 hours with 200 %M etoposide or 3%M
thapsigargin and assessed apoptosis. As expected, the etoposide and
thapsigargin treatments each induced apoptosis in the 10T1/2 fibroblasts and
ER-MyoD:10T1/2 fibroblasts, both in the absence of estradiol. However, while
the addition of estradiol had no effect on the apoptosis induced by etoposide or
thapsigargin in the 10T1/2 fibroblasts, the apoptotic response was increased over
two times by the presence of estradiol in ER-MyoD:10T1/2 fibroblasts (Figure
19).
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Figure 19. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads enhanced apoptosis induced by agents
which cause DNA damage or ER-Stress.

Parental 10T1/2 fibroblasts or ER-

MyoD:10T1/2 fibroblasts were cultured in GM in (A) with either vehicle or 200 %M
etoposide or in (B) 3 %M thapsigargin and +/- estradiol 24 hours as indicated. Next day,
detached cells and adherent cells were collected then counted. Percent apoptosis was
calculated (number of detached cells/ detached cells plus adherent cells). Shown is an
average of triplicates (mean +/- standard deviation) from one experiment that is
representative of three independent experiments.
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3.3 MyoD mediated regulation of the apoptotic response correlates with the
level of induction of the pro-apoptotic Bcl-2 family member PUMA

We have previously reported that the proapoptotic Bcl-2 member PUMA
(p53 up regulated modulator of apoptosis) expression increases when cells are
switched to DM for three hours (Shaltouki et al. 2007). We have also previously
shown that this induction of PUMA is p53 independent. Additionally, when
myoblasts are untreated, basal levels of PUMA expression are difficult to detect.
Our lab has also shown that PUMA plays a critical role in the apoptosis
associated with differentiation of skeletal myoblasts (Shaltouki et al. 2007).
Based on these data, we hypothesized that MyoD may play a role in the
induction of PUMA expression as a consequence of culture in DM. First, we
assayed for the induction of PUMA in response to culture in DM in parental and
control transduced 23A2 or C2C12 myoblasts and compared these levels to their
respective shMyoD clones. After switching the cells to DM for three hours, we
collected total cellular RNA utilizing standard Trizol protocol followed by RT-PCR.
We found that PUMA mRNA induction was impaired in 23A2:shMyoD and
C2C12:shMyoD clones as compared to the parental and vector transduced
control myoblasts (Figure 20). Additionally, after 3 hours in DM, we found PUMA
protein induction was also impaired in 23A2:shMyoD and C2C12:shMyoD clones
as compared to the parental and vector transduced control myoblasts (Figure
21).
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Figure 20. Elevated PUMA mRNA expression levels as a consequence of
serum withdraw correlates with MyoD expression levels in myoblasts. In
(A) 23A2 myoblast parental, vector and shMyoD clones and in (B) C2C12 myoblast
parental, vector and shMyoD clones were screened for PUMA induction. Equal number
of cells was plated and the next day given either fresh GM or DM for 3 hours. Total
cellular RNA was isolated using standard TRIZOL method. Quantitative RT-PCR for
PUMA was performed using the Quantitech Sybr Green PCR kit (Qiagen). Fluorescence
was detected using an Opticon Monitor (MJ Research) Opticon software was used to
calculate cycle threshold (Ct) values. The Ct value for PUMA PCR product was
normalized to the Ct value for Actin PCR product run parallel. Shown is an average of
triplicates (mean +/- standard deviation) from one experiment that is representative of
three independent experiments.
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Figure 21. Elevated PUMA protein expression levels as a consequence of
serum withdraw correlates with MyoD expression levels in myoblasts. In (A)
23A2 myoblast parental, vector and shMyoD clones and in (B) C2C12 myoblast
parental, vector and shMyoD clones, equal numbers of cells were plated and the
next day given either fresh GM or DM for 3 hours. In (A) whole cell lysates were
collected then separated by SDS-Page prior to electrophoretic transfer. Immunoblot
analysis for PUMA expression was preformed. Actin was monitored for equal loading.
Shown are results from one experiment that are representative of 2 independent
experiments.
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We next compared the expression of PUMA in 10T1/2 fibroblasts and ERMyoD:10T1/2 fibroblasts in response to culture in DM in the absence or presence
of estradiol. Estradiol addition in DM resulted in approximately a four fold
increase in PUMA mRNA and protein in the ER-MyoD:10T1/2 fibroblasts, yet had
no effect on the level of PUMA mRNA or protein in the 10T1/2 fibroblasts (Figure
22).
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Figure 22. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads to PUMA induction in response to
serum withdrawal.

Parental 10T1/2 fibroblasts or 10T1/2 ER: MyoD expressing

fibroblasts were cultured in DM 3 hours. In (A) total RNA was isolated using the standard
Trizol method. RT-PCR for PUMA was performed and PCR product was separated on
an ethidium bromide stained agarose gel. Images were analyzed using the GE
Healthcare Life Sciences Typhoon 9410 Imager and band volume quantified using

ImageQuant software (v5.2). Shown is an average of triplicates (mean +/- standard
deviation) from one experiment that is representative of three independent experiments.
In (B) whole cell lysates were collected prior to separation by SDS-PAGE and
electrophoretic transfer to PVDF. Immunoblot analysis for PUMA expression was
performed. Actin was monitored for equal loading. Shown are results from one
experiment that are representative of 2 independent experiments.
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Some labs have reported the p53–dependent induction of PUMA in
response to etoposide (Michalak et al. 2008) or thapsigargin (Li et al. 2006) in a
variety of non-muscle cell types. Since we have determined that MyoD
contributes to the apoptosis induced by these agents (Figures 18-20), we
examined the contribution to the induction of PUMA in response to either
etoposide or thapsigargin. First we performed a time course and concentration
course analysis for treatment with etoposide or thapsigargin and determined that
the minimum time and concentration required to increase the level of PUMA
expression was 200 %M and eight hours for etoposide and 3 %M and 12 hours for
thapsigargin. We then monitored the induction of PUMA as a consequence of
culture with either etoposide or thapsigargin in GM. When comparing parental
and control transduced 23A2 and C2C12 myoblasts to their respective cones, we
found both PUMA mRNA as well as protein increased as expected in the
parental and control transduced myoblasts; however, PUMA induction was
impaired in the 23A2:shMyoD and C2C12:shMyoD clones in response to culture
with etoposide or thapsigargin (Figures 23-26). This indicates the presence of
MyoD is required for the induction of PUMA expression in response to inducers
of DNA damage or ER-stress.
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Figure 23. Reduced MyoD expression in 23A2 myoblasts abrogates
increased PUMA expression in response to etoposide. Equal numbers of cells
were plated and the next day treated +/- 200 %M etoposide for 8 hours. In (A) total RNA
was isolated using standard Trizol method. RT-PCR for PUMA was performed and PCR
products were separated on an ethidium bromide stained agarose gel. Images were
analyzed using GE Healthcare Life Sciences Typhoon 9410 Imager and band volume
quantified using ImageQuant software (v5.2). Shown is an average of triplicates (mean
+/- standard deviation) from one experiment that is representative of three independent
experiments. In (B) whole cell lysates were collected prior to separation by SDS-PAGE
and electrophoretic transfer to PVDF. Immunoblot analysis for PUMA expression was
performed. Actin was monitored for equal loading. Shown are results from one
experiment that are representative of 2 independent experiments.
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Figure 24. Reduced MyoD expression in 23A2 myoblasts abrogates
increased PUMA expression in response to thapsigargin. Equal numbers of
cells were plated and the next day treated +/- 3 %M thapsigargin for 12 hours. In (A) total
RNA was isolated using standard Trizol method. RT-PCR for PUMA was performed and
PCR products were separated on an ethidium bromide stained agarose gel. Images
were analyzed using GE Healthcare Life Sciences Typhoon 9410 Imager and band
volume quantified using ImageQuant software (v5.2). Shown is an average of triplicates
(mean +/- standard deviation) from one experiment that is representative of three
independent experiments. In (B) whole cell lysates were collected prior to separation by
SDS-PAGE and electrophoretic transfer to PVDF. Immunoblot analysis for PUMA
expression was performed. Actin was monitored for equal loading. Shown are results
from one experiment that are representative of 2 independent experiments.
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Figure 25. Reduced MyoD expression in C2C12 myoblasts abrogates
increased PUMA expression in response to etoposide. Equal number of cells
was plated and the next day treated +/- 200 %M etoposide for 8 hours. In (A) total RNA
was isolated using standard Trizol method. RT-PCR for PUMA was performed and PCR
product was separated on an ethidium bromide stained agarose gel. Images were
analyzed using GE Healthcare Life Sciences Typhoon 9410 Imager and band volume
was quantified using ImageQuant software (v5.2). Shown is an average of triplicates
(mean +/- standard deviation) from one experiment that is representative of three
independent experiments. In (B) whole cell lysates were collected prior to separation by
SDS-PAGE and electrophoretic transfer to PVDF membrane. Immunoblot analysis for
PUMA expression was performed. Actin was monitored for equal loading. Shown are
results from one experiment that are representative of 2 independent experiments.
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Figure 26. Reduced MyoD expression in C2C12 myoblasts abrogates
increased PUMA expression in response to thapsigargin. Equal numbers of
cells were plated and the next day treated +/- 3 %M thapsigargin for 12 hours. In (A) total
RNA was isolated using standard Trizol method. RT-PCR for PUMA mRNA expression
was performed and PCR product was separated on an ethidium bromide stained
agarose gel. Images were analyzed using the GE Healthcare Life Sciences Typhoon
9410 Imager and band volume quantified using ImageQuant software (v5.2). Shown is
an average of triplicates (mean +/- standard deviation) from one experiment that is
representative of three independent experiments. In (B) whole cell lysates were collected
prior to separation by SDS-PAGE and electrophoretic transfer to PVDF membrane.
Immunoblot analysis for PUMA expression was performed. Actin was monitored for
equal loading. Shown are results from one experiment that are representative of 2
independent experiments.
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Finally, we compared the expression of PUMA in ER-MyoD:10T1/2
fibroblasts and parental 10T1/2 fibroblasts cultured with either etoposide or
thapsigargin in the absence or presence of estradiol in GM. Estradiol treatment
combined with etoposide resulted in approximately a 3.5 fold induction in PUMA
mRNA and protein in the ER-MyoD:10T1/2 fibroblasts, yet had no effect on the
level of PUMA mRNA or protein on parental 10T1/2 fibroblasts treated with
etoposide (Figure 27). Likewise, estradiol treatment combined with thapsigargin
in GM resulted in over a three fold increase in PUMA mRNA and protein in the
ER-MyoD:10T1/2 fibroblasts, yet had no effect on the level of PUMA mRNA or
protein induction in the parental 10T1/2 fibroblasts treated in the same manner
(Figure 28).
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Figure 27. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads to PUMA induction in response to
etoposide. A. Parental 10T1/2 fibroblasts or 10T1/2 ER: MyoD expressing fibroblasts
were cultured in GM + 200 %M etoposide +/- estradiol for 8 hours. In (A) total RNA was
isolated using standard Trizol method. RT-PCR for PUMA was performed and PCR
products were separated on an ethidium bromide stained agarose gel. Images were
analyzed using the GE Healthcare Life Sciences Typhoon 9410 Imager and band
volume was quantified using ImageQuant software (v5.2). Shown is an average of
triplicates (mean +/- standard deviation) from one experiment that is representative of
three independent experiments. In (B) whole cell lysates were collected prior to
separation by SDS-PAGE and electrophoretic transfer to PVDF membrane. Immunoblot
analysis for PUMA expression was performed. Actin was monitored for equal loading.
Shown are results from one experiment that are representative of 2 independent
experiments.
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Figure 28. MyoD activation in 10T1/2 fibroblasts expressing an estrogen
receptor MyoD fusion protein leads to PUMA induction in response to
thapsigargin.

A. Parental 10T1/2 fibroblasts or 10T1/2 ER: MyoD expressing

fibroblasts were cultured in GM + 3 %M thapsigargin +/- estradiol for 12 hours. In (A) total
RNA was isolated using standard Trizol method. RT-PCR for PUMA was performed and
PCR product was separated on an ethidium bromide stained agarose gel. Images were
analyzed using GE Healthcare Life Sciences Typhoon 9410 Imager and band volume
quantified using ImageQuant software (v5.2). Shown is an average of triplicates (mean
+/- standard deviation) from one experiment that is representative of three independent
experiments. In (B) whole cell lysates were collected prior to separation by SDS-PAGE
and electrophoretic transfer to PVDF membrane. Immunoblot analysis for PUMA
expression was performed. Actin was monitored for equal loading. Shown are results
from one experiment that are representative of 2 independent experiments.
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Our lab has previously shown that PUMA induction in skeletal myoblasts
when cultured in DM is p53 independent. This experiment utilized the
pharmacological p53 inhibitor pifithrin! (Komarov et al. 1999). We saw PUMA
was still induced in the presence of pifithrin! (Shaltouki et al. 2007). Additionally,
other labs (Han et al. 2001) have shown that PUMA induction in response to
culture in DM is p53-independent in human tumor cells including HT29 cells
which express a mutant form of p53, Jurkat cells which are p53 negative, and
p53 null HL60. Since our data has lead us to believe that MyoD may be acting in
place of p53 in skeletal myoblasts with regard to the induction of PUMA in
response to serum withdrawal, in response to etoposide as well as thapsigargin,
we needed to verify that basal levels of p53 were not altered during the
transduction of these myoblasts with the shRNA against MyoD. We performed
an immunoblot analysis for the expression of p53 and found that when
comparing parental and control transduced 23A2 and C2C12 myoblasts to their
respective clones, basal p53 levels remained unchanged in the shMyoD clones
with respect to the parental and control myoblasts in both 23A2 and C2C12 cell
lines (Figure 29).
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A.

B.

Figure 29. Basal expression levels of p53 in myoblasts transduced with
shRNA against MyoD is not affected. In (A), 23A2 myoblast parental, vector
and shMyoD clones and in (B) C2C12 myoblast parental, vector and shMyoD
clones,p53 expression was detected by immunoblot analysis. Actin was monitored to
ensure equal loading. Shown are results from one experiment that are representative of
2 independent experiments.
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Finally, in an effort to determine if PUMA induction in response to growth
factor withdrawal required de novo protein synthesis, we cultured 23A2 and
C2C12 myoblasts in GM or DM for three hours in the presence or absence of
cyclohexamide.

Cyclohexamide

inhibits

protein

synthesis

by

blocking

translational elongation. PUMA mRNA is induced in response to culture in DM in
both 23A2 and C2C2 myoblasts. When cyclohexamide is added to DM, PUMA
mRNA induction is still induced (Figure 30). We also found that in ERMyoD:10T1/2 fibroblasts that PUMA mRNA is induced in DM containing
estradiol.

This induction is still occurs in the presence of cyclohexamide,

however in the absence of estradiol, this induction is abrogated (Figure 31). This
finding indicates that de novo protein synthesis is not required for the induction of
PUMA mRNA and suggests that MyoD could be directly affecting the increase of
PUMA mRNA levels.
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Figure 30. PUMA mRNA induction does not require de novo translation in
myoblasts. In (A) 23A2 and in (B) C2C12 myoblasts were cultured in GM, DM or DM
+ cyclohexamide (CHX) for 3 hours. Total RNA was isolated using standard the Trizol
method. RT-PCR for PUMA was performed and PCR products were separated on an
ethidium bromide stained agarose gel. Images were analyzed using the GE Healthcare
Life Sciences Typhoon 9410 Imager and band volume was quantified using ImageQuant
software (v5.2). Shown is an average of triplicates (mean +/- standard deviation) from
one experiment that is representative of three independent experiments.
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Figure 31. PUMA mRNA induction does not require de novo translation in
10T1/2 fibroblasts expressing estrogen receptor MyoD fusion protein.
10T1/2 ER: MyoD expressing fibroblasts were cultured in GM, DM or DM +
cyclohexamide (CHX) in the absence (A) or in the presence (B) of estradiol for 3 hours.
Total RNA was isolated using the standard Trizol method. RT-PCR for PUMA was
performed and PCR products were separated on an ethidium bromide stained agarose
gel. Images were analyzed using the GE Healthcare Life Sciences Typhoon 9410
Imager and band volume was quantified using ImageQuant software (v5.2). Shown is an
average of triplicates (mean +/- standard deviation) from one experiment that is
representative of three independent experiments.
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CHAPTER IV
DISCUSSION
4.1 Overview
The discovery of the myogenic transcription factor MyoD by Lassar et al.
in 1986, followed by the cloning of the other myogenic factors Myf5 (Braun et al.
1989), myogenin (Wright et al. 1989)and MRF4 (Rhodes and Konieczny 1989)
soon after, lead to an entirely new area of muscle research. These initial studies
showed expression of any of these myogenic factors could convert multipotent
stem cells to the myogenic cell lineage. However, later studies revealed these
factors all are temporally expressed during the differentiation process and that
MyoD and Myf5 are responsible for determination while myogenin and MRF-4
are required for differentiation. Thus, skeletal myoblasts serve as an excellent
model system to study determination and differentiation. With our findings, we
can now state that skeletal myoblasts can also be a model system for the study
of differentiation and the associated apoptosis.
MyoD has long been recognized for its role as the master regulatory
transcription factor responsible for specification and for driving the differentiation
process following cell cycle exit. With our findings, we conclude that MyoD also
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serves in a pro-apoptotic capacity. The processes of differentiation and the
associated apoptosis are mutually exclusive biological endpoints. For this to be
true there must be a point of bifurcation in the signaling events leading to the
decision to differentiate or undergo apoptosis.
It has been the focus of the Weyman lab to determine the molecular
mechanisms responsible for the fact that a subpopulation of myoblasts will
undergo apoptosis rather than differentiation when cultured in the absence of
serum. We have previously shown the pro-apoptotic Bcl-2 family member PUMA
is required for apoptosis in skeletal myoblasts upon serum withdrawal.
Additionally, we have demonstrated that PUMA is not required for differentiation.
Specifically, our lab has previously shown that myoblasts transduced with
lentivirus expressing shRNA against PUMA mRNA, when cultured in DM no
longer underwent apoptosis but can still differentiate as evidenced by the
expression of MHC. Interestingly, increased PUMA expression in skeletal
myoblasts in response to serum withdrawal is not a p53 mediated event. When
23A2 myoblasts were cultured in DM with the addition of the p53 inhibitor
pifithrin, PUMA mRNA and protein expression still increased (Shaltouki et al.
2007). Non-p53 mediated increase in PUMA expression occurs in other cells in
response to serum withdrawal, including the human cancer line HT29 cells (p53
mutant) , Jurkat cells, and HL60 cells (both p53 null) (Han et al. 2001). Sp1 and
p73 were later found to regulate PUMA induction under serum withdrawal
conditions in HT29 cells (Ming, et al. 2008). PUMA expression levels in skeletal
myoblasts in response to culture in DM correlates to the expression levels of
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MyoD (Karasarides, et al. 2006). We have shown herein that MyoD is necessary
for both differentiation as well as the associated apoptosis. Since MyoD is
common to both differentiation and apoptosis, whereas PUMA is only necessary
for apoptosis, this appears to be a point of bifurcation in the signaling pathways
required to decide between undergoing differentiation or apoptosis. (Figure 32).

MyoD
DM

DM
etoposide
thapsigargin

PUMA

p21CDK, myogenin

apoptosis

differentiation

Figure 32. A Role for MyoD in the regulation of PUMA and apoptosis. The
transcription factor MyoD has long been recognized for its direct role in the regulation of
myogenin expression and the expression of other genes controlling muscle
differentiation. We provide data to support a novel pro-apoptotic role in the regulation of
PUMA expression and apoptosis. Direct regulation of PUMA expression by MyoD, as
well as the molecular mechanisms responsible for determining whether MyoD induces
p21 CDKI, myogenin and differentiation or MyoD’s induction of PUMA and apoptosis
awaits further investigation.
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MyoD is acknowledged as the master regulatory transcription factor that
controls the expression of many genes in a temporal fashion. MyoD can directly
induce the expression of the cell cycle inhibitor p21 CDKI and Rb to induce cell
cycle withdrawal. MyoD can also induce the expression of cyclin D3 during
differentiation which appears contradictory to the typical functions of cyclins
(Cenciarelli et al. 1999). Additionally, MyoD can directly induce the expression of
myogenin, but not until the cell has exited the cell cycle. Interestingly, MyoD is
bound to the myogenin promoter even in a proliferative state but remains
transcriptionally silent (Mal and Harter 2003). Myogenin is expressed only upon
chromatin remodeling in response to cues to differentiate (de la Serna et al.
2001). Mef2d is yet another gene MyoD induces. MyoD along with Mef2d cooperatively regulate the expression of late differentiation genes such as MHC

Despite

the

abundance

of

understanding

of

skeletal

myoblast

differentiation and the molecular mechanisms responsible, there is relatively very
little known in regards to the molecular mechanisms that drive skeletal myoblast
apoptosis. Our challenge now is to elucidate the molecular mechanisms which
allow MyoD to induce PUMA and apoptosis in a sub population of myoblasts
instead of muscle specific genes and differentiation. We can speculate that the
decision for MyoD to induce PUMA and apoptosis or myogenin and
differentiation is a consequence of the cells position in the cell cycle. Previous
reports have shown that manipulating the expression of cell cycle regulatory
proteins can either block or induce apoptosis in myoblasts or in MyoD-expressing
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fibroblasts (Wang and Walsh 1996). Expression of the CDK inhibitor p21
promotes survival and additionally, forced expression of p21 leads to resistance
to differentiation associated apoptosis and required Rb. Rb-/- myogenic cells are
more susceptible to apoptosis even with normal increased p21 expression and
reduced CDK expression (Wang and Walsh 1996, and Wang et al. 1997).
Reduced levels of Rb result in massive apoptosis (Zacksenhaus et al. 1996). We
have an asynchronous population of myoblasts which are neither Rb nor p21
deficient. Based on this information, we believe the difference in cells which
undergo apoptosis rather than differentiation is their position near the G1/S
checkpoint where p21 no longer blocks Rb activation by cyclin dependent
kinases. Inhibition of Rb activity leads to an increase in E2F. E2F leads to the
increase of the apoptosis stimulating protein of p53-2 (ASSP). Increased ASSP
then stimulates p53 which will, in turn, up-regulate pro-apoptotic genes (Chen et
al. 2005).

During neurogenesis, neuronal apoptosis occurs at the G1/S

restriction point. E2F is repressed by Rb, which is required for survival of neurons
(Liu and Greene 2001).

We believe the mechanism might be similar which

allows MyoD to either induce PUMA and apoptosis or myogenin and
differentiation.
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Initial studies of apoptosis involved C. elegans as the model system
(Review, Horvitz 1999). During the development of C. elegans, 1090 cells are
formed but 131 of these cells die via apoptosis. The study of the molecular
mechanisms involved in the death of these cells identified a set of four genes
which co-ordinate the apoptotic process. Egl-1 (egg-laying defective), ced-9 (cell
death defective), ced-4 and ced-3 where found, when mutational analyses were
conducted, to interfere with cell death. Egl-1 is a pro-apoptotic molecule and acts
to inhibit ced-9, an anti-apoptotic molecule. Ced-4, an adapter molecule,
activates ced-3, a protease. Ced-4 can be inhibited by ced-9, thereby blocking
the activation of ced-3. These factors have been found to have homologues in
vertebrate systems. Ced-3 is akin to caspase 3, ced-4 is most similar to the
adapter molecule Apaf-1, which makes up part of the apoptosome, ced-9 is
homologous to the anti-apoptotic Bcl-2 protein and Egl-1 shares similarity to proapoptotic BH-3 only Bcl-2 family members. (Figure 33).
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Figure 33. Apoptotic factors discovered in C. elegans and mammalian
homologs. Factors involved in apoptosis during development were first
discovered in C. elegans. Later, homologs of these factors were discovered in
mammalian systems. Egl-1, a BH3 only protein, was found to inhibit Ced-9,
whereas Ced-9 inhibited Ced-4. By Egl-1 blocking the activity of Ced-9, Ced-4
was activated, leading to the activation of Ced-3. In mammalian cells, Egl-1 is
most like PUMA, also a BH3 only protein. The mammalian homolog of Ced-9 is
the antiapoptotic Bcl-2. Ced-4 most closely relates to the mammalian adapter
molecule APAF-1, which makes up part of the apoptosome, and Ced-3 homolog
in the mammalian system is Caspase 9, an initiator caspase.
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MyoD is a basic helix-loop-helix (bHLH) transcription factor and, to our
knowledge, the only other bHLH transcription factors that are known to play a
role in cell specification, differentiation and apoptosis are the Daughterless-like
(HLH-2) and Achaete-scute-like bHLH (HLH-3) transcription factors expressed in
C. elegans, and is responsible for neuronal development. HLH-2 and HLH-3 has
been shown to form heterodimers and bind to E box consensus sequences (5’CANNTG-3’) much like MyoD:E protein heterodimers in mammalian systems.
HLH-2:HLH-3 heterodimers are responsible for the transcription of Egl-1 by
binding to E-boxes found in a cis- regulatory region of the Egl-1 promoter. Egl-1
is a pro-apoptotic BH3 only Bcl-2 protein as is PUMA. Egl-1 expression is
regulated by HLH-2:HLH3 heterodimer, which resemble MyoD:E protein
heterodimers, both of which bind E-boxes in promoter regions. Based on this
information and our data presented herein, we believe MyoD is an excellent
candidate transcription factor in skeletal myoblasts responsible for the expression
of PUMA (Figure 33).

The idea that a single transcription factor can regulate genes responsible
for mutually exclusive physiological endpoints is not without precedent in
mammalian systems. The Myc transcription factor has the dual capacity to
induce either proliferation or apoptosis. Regulation of proliferation by Myc is
through transcriptional targets such as cdc25 and CDK4. Myc also functions in
apoptosis by indirectly inducing the release of cytochrome c from the
mitochondria and may involve the pro-apoptotic Bcl-2 family member Bax.
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Additionally, Myc has been shown to activate p19 ARF, which in turn induces p53
dependent gene expression (Pelengaris et al. 2002).

The transcription factor p53 also performs several functions. p53 plays an
important role in growth arrest by the transcription of p21 CDKI. Expression of
p21 CDKI blocks progression through the cell cycle at the G1/S phase
checkpoint. p53 carries out pro-apoptotic functions by inducing the expression of
PUMA, as well as other pro-apoptotic Bcl-2 family members, which leads to the
activation of the intrinsic apoptotic pathway. The ability of MyoD to induce growth
arrest and differentiation or apoptosis is analogous to the ability of p53 to induce
growth arrest or apoptosis in response to DNA damage in other cell types.
Interestingly, p53 has been shown to be critical in myoblast differentiation. p53
has been shown to induce differentiation of mouse embryonic stem cells (ESCs)
through the suppression of the protein Nanog, which is required to block
differentiation of ESCs (Lin et al. 2005). Conversely, p53 has been shown to
block differentiation of MEF to adipocytes. However, this too, is likely achieved by
transcriptional inhibition of PPAR! and/or CEBP! (Molchadsky 2008). Utilizing
C2C12 myoblasts, a dominant negative form of p53 was expressed which binds
to endogenous p53, resulting in transcription inhibition. These myoblasts failed to
upregulate Rb under differentiation conditions (Porrello et al. 2000). Rb has dual
functions contributing to cell cycle arrest and expression of late myogenic factors.
In myoblasts with defective p53, cell cycle gene expression was not altered and
myogenin was still expressed, however, MHC failed to be expressed (Huh et al.
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2004). Even more fascinating is that p53 in skeletal myoblasts does not affect
differentiation associated apoptosis. Utilizing a p53 reporter construct upstream
of GFP gene, C2C12 myoblasts were transfected followed by induction of DNA
damage by adriamycin treatment while culturing in differentiation media. The
authors found no fluorescence in apoptotic population at anytime within 48 hours
however fluorescence was visualized in all differentiated cells after 24 hours after
culture in DM (Cerone et al. 2000). This data shows p53 is not required for
apoptosis in skeletal myoblasts. The future challenge previously mentioned, to
understand the molecular mechanism that allows MyoD to induce PUMA and
apoptosis, instead of p21 CDKI, cell cycle exit and muscle specific genes as
described in Figure 32, resembles the long standing challenge to understand the
same features of p53 in the choice to induce p21CDKI or PUMA (Vousden et al.
2009).

We, and others, have previously suggested an apoptotic role for MyoD.
We reported that the level of MyoD expression correlated with the apoptotic
potential as well as the differentiation potential in response to culture in DM
(Karasarides et al. 2005). Another group has reported that over-expression of
ectopic MyoD in cells lacking functional retinoblastoma protein (Rb) induces
apoptosis (Peschiaroli et al. 2002 and Gottifredi et al. 1999). This MyoD induced
apoptosis was also shown to be p53 independent (Gottifredi et al. 1999). As
23A2 myoblasts, C2C12 myoblasts and 10T1/2:ER-MyoD fibroblasts, are not Rb
deficient (data not shown), the data we have presented in this manuscript
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indicates that endogenous levels of MyoD can confer the ability to undergo
apoptosis in cells with functional Rb. In support of our findings, a recent report
using primary MyoD -/- satellite derived myoblasts, upon transplantation into
mice after cardiotoxin induced muscle injury, showed enhanced survival upon
engraftment. It is important to note here that these myoblasts are differentiation
delayed but not deficient and this can be attributed to a five fold increase in the
expression of Myf5, which has been shown to compensate for MyoD during
skeletal myoblast differentiation during embryonic development (Rudnicki et al.
1992). In agreement with our previous findings that PUMA is required for
myoblast apoptosis (Shaltouki et al. 2007), ectopic expression of PUMA in these
MyoD -/- satellite cells restored their apoptotic potential (Asakura et al. 2007).

We also demonstrate here that MyoD plays a role in responding to etoposideinduced apoptosis. MyoD-/- myoblasts were also resistant to UV-induced
apoptosis showing a four fold reduction in the number of apoptotic cells after
treatment in comparison to MyoD +/+ myoblasts (Asakura et al. 2007). Taken
together, these results suggest that MyoD plays a role in responding to DNA
damage. Typically, tumor suppressor activity has been attributed to molecules
like p53, which mediate apoptosis in response to DNA damage (Vousden and
Prives 2009). The significance of a pro-apoptotic role for MyoD with respect to
the development of Rhabdomyosarcoma has not yet been explored. Further, we
show that MyoD also plays a role in responding to ER-stress induced apoptosis.
Since ischemia elicits an ER-stress induced up-regulation of PUMA expression
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(Toth et al. 2006 and Nickson et al. 2007), the importance of a pro-apoptotic role
for MyoD in ischemia induced muscle damage should also be explored.

Finally, we show that the role of MyoD in responding to either DNA
damage (as induced by etoposide treatment) or ER-stress (as induced by
thapsigargin), similar to MyoD’s role in responding to culture in DM (serum
withdrawal), involves PUMA (Figure 31). In the absence of an apoptotic stimulus,
such as culture in DM or treatment with etoposide or thapsigargin in GM, reduced
levels of MyoD has no detectable effect on basal PUMA expression (data not
shown). What remains to be explored is whether the mechanism of MyoD’s
induction of PUMA in response to DM is similar to the mechanisms initiated by
culture with agents that cause DNA damage or ER-stress.

What we mean by this is MyoD may have different transcriptional partners
at different promoter locations. MyoD binds E proteins at E boxes of myogenic
genes, however, the binding partner or other transcriptional enhancers may be
involved in the expression of non-myogenic genes. As an example, under
hypoxic conditions, MyoD drives the transcription of UCP3 in differentiated
C2C12 myoblasts and UCP3 expression is enhanced by the transcription factor
ATF-1 (Lu et al. 2008). The expression of UCP3 by MyoD is achieved by binding
to a non-canonical E box in the UCP promoter. Additionally, under normal
metabolic situations, UCP3 transcription is achieved by MyoD and PPAR! rather
than ATF-1 (Solanes et al. 2003).
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The report demonstrating the increased survival of MyoD-/- myoblasts
correctly suggests that targeting MyoD could be beneficial to myoblast transfer
strategies to aid in the expansion of muscle stem cells (Asakura et al. 2007).
Again, we must reiterate the fact that MyoD-/- satellite cell-derived myoblasts
display delayed differentiation (Sabourin et al. 1999) and are also deficient in
muscle regeneration (Megeney et al. 1996). Our findings show that PUMA plays
a critical role in the apoptotic process, but plays no role in the differentiation
process. This suggests that PUMA may also be a good candidate for therapeutic
manipulation to enhance the regenerative potential of adult muscle stem cells
and to increase the efficacy of myoblast transfer therapies (Shaltouki et al. 2007).
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4.2 Future Directions
Now we have provided data to show that MyoD is sufficient and necessary
for the induction of apoptosis in response culture in DM (serum withdrawal),
etoposide treatment (DNA damage) or thapsigargin treatment (ER-stress) in
skeletal myoblasts. Our next step is to identify the molecular mechanisms by
which induction of PUMA expression occurs. To this end, we have proposed a
set of experiments to test whether MyoD directly controls PUMA expression.
Additionally, since MyoD is necessary for apoptosis in skeletal myoblasts, we
must look at other molecules involved in the apoptotic process and determine
what effects can be attributed to MyoD.

Our first hypothesis is that MyoD directly regulates PUMA expression. In
support of this hypothesis, we have performed in silico analysis of a 5kb region of
the murine PUMA promoter utilizing the online promoter analysis program
MatInspector. We have found at least 5 potential canonical E box MyoD:E12/47
heterodimer binding sites within this region. This program selects only canonical
binding sites for MyoD. As MyoD can bind non-canonical E boxes within
promoters, it is very possible there are more potential binding sites within this
region. In order to test our hypothesis, we propose the following experiments. We
will begin by creating a pGLC3 basic luciferase reporter construct containing a
portion of the PUMA promoter cloned upstream of the luciferase gene. To create
this construct, we will PCR amplify approximately a 2kb 5’ region of the PUMA
gene and clone into the pGLC basic luciferase reporter construct. This or control
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vector will be transfected into 23A2 and C2C12 myoblasts and next day,
luciferase activity will be measured following culture in GM as compared to DM.
We will also use this same method utilizing the ER-MyoD 10T1/2 fibroblasts +/estradiol treatment cultured in GM or DM. Once we determine MyoD
responsiveness, we will then generate a series of truncations to the 5’ promoter
region to identify the minimal MyoD responsive cis regulatory region. We will then
transfect the vector containing the minimal region into 23A2 and C2C12
myoblasts silenced for MyoD, culture in GM or DM and assess for luciferase
activity. The luciferase activity will be normalized to Renilla luciferase for
transfection efficiency. Renilla luciferase activity is not affected by culture in GM
versus DM.

In order to determine if this interaction is through direct binding of the
PUMA promoter, we will next perform electrophoretic mobility shift assay (EMSA)
analysis using the minimal MyoD responsive cis-regulatory region previously
determined. We will prepare nuclear extracts of 23A2 and C2C2 myoblasts
cultured in GM or DM and from ER-MyoD 10T1/2 fibroblasts cultured in GM or
DM in the absence or presence of estradiol. Extracts will be incubated with a
radiolabelled minimal cis-regulatory region as described previously then
subjected to EMSA. To ensure specificity, EMSA will also be performed using a
mutant version of this regulatory region and competition experiments will be
carried out using unlabelled sequences. The identity of the protein in the shifted
complex will be examined using an anti-MyoD antibody. To serve as a negative
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control, supershift analysis will be performed using anti-IgG. AS a positive
control, EMSA and supershift assays will be performed using the known MyoD
cis regulatory sequence from the myogenin gene. We will duplicate these
experiments utilizing the 23A2 and C2C12 myoblasts silenced for MyoD
expression.

In order to test if the previous association of MyoD and the PUMA
promoter

occur

specifically

in

vivo,

we

will

perform

chromatin

immunoprecipitation (CHiP) analysis using chromatin isolated from 23A2 and
C2C12 myoblasts cultured in GM or DM and ER-MyoD10T1/2 fibroblasts
cultured in GM or DM in the absence or presence of estradiol. Chromatin will be
cross-linked using 1% formaldehyde then digested with MNase to achieve a
length between 200-100bp fragments. Immunoprecipitation will be performed
using

EZ

CHiP

chromatin

Immunoprecipitation

kit

per

manufacturers’

instructions. Chromatin will be pre-cleared using A/G sepharose after blocking
using salmon sperm DNA and BSA. A portion will be set aside as an input
control, while the remainder of the sample will be immunoprecipitated using antiMyoD antibody. Samples will be treated with proteinase K, cross-linking reversal
then quantitative RT-PCR will be performed to detect the putative MyoD cisregulatory

sequence

identified

previously.

Negative

control

will

be

immunoprecipitation using appropriate IgG and positive control will include PCR
for the myogenin gene.
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Another part of this project is to determine what role serine proteases play
in skeletal myoblast apoptosis. In rat fibroblasts, DNA damage and ER stress
induced apoptosis resulted in activation of serine proteases. Preliminary data
collected by our lab has shown that serine proteases are activated within three
hours of culture in DM in 23A2 skeletal myoblasts. We will continue to investigate
serine protease activation in response to various apoptotic inducing factors.
Using FLISP (Fluorescently labeled inhibitor of serine protease) to selectively
and covalently label in situ active serine proteases, we have found many serine
proteases are activated upon culture in DM. When myoblasts cultured in DM
were treated with pharmacological inhibitors of serine proteases, we found
cytochrome C release and DNA fragmentation was abrogated. This was also
observed in 10T1/2 fibroblasts expressing ectopic MyoD. To this end we
hypothesize MyoD is both sufficient and necessary to induce mitochondrial
disruption and apoptosis through the increased activation of serine proteases. To
investigate this hypothesis, we will assess the activation of serine proteases in
myoblasts cultured in GM or DM and ER-MyoD:10T1/2 fibroblasts cultured in GM
or DM in the absence or presence of estradiol. We will then assess activation of
serine proteases in myoblasts silenced for MyoD. We will then immunoprecipitate
the activated serine proteases labeled with FLISP using an anti-FLISP antibody.
The immunoprecipitated activated serine proteases will be subjected to
separation by SDS-PAGE, followed by visualization of bands, which will be then
sent for sequence analysis. If samples subjected to immunoprecipitation cannot
be analyzed, we will separate samples by 2D gel electrophoresis and visualize
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spots using GE Healthcare Life Sciences Typhoon 9410 Imager which will detect
the FLISP labeled activated serine proteases. Spots can then be sent for
sequence analysis.

4.3 Conclusions

Differentiation and apoptosis are coordinately regulated in many cell
types, and to date, this coordinate regulation is not well understood. We have
identified in this body of work that the muscle regulatory transcription factor
MyoD is a molecule common to both the induction of differentiation as well as
apoptosis. Further, we have determined that MyoD is both necessary and
sufficient to contribute to the increased expression of the pro-apoptotic Bcl-2
family member PUMA, a molecule critical to only the apoptotic process. Finally,
we have determined that MyoD and the corresponding induction of PUMA
contribute to the apoptotic process in response to treatments with etoposide or
thapsigargin. Thus, our data suggests that MyoD is critical to the coordination of
both differentiation and apoptosis. Additionally, and most exciting is that MyoD
also serves as a modulator of apoptosis in response to more traditional and
widely applicable apoptotic agents.

While this body of work has offered novel and exciting new roles for MyoD
in skeletal myoblasts, it is in no way the end to the important question, what is
the mechanism responsible for the decision to undergo either differentiation or

90

apoptosis. We look forward to the future in continuing these studies as outlined
in future directions, and delving in further to elucidate the mechanisms MyoD is
responsible in contributing to apoptosis.
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